<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006861.pub2" GROUP_ID="RENAL" ID="366806092606430319" MERGED_FROM="" MODIFIED="2013-08-06 23:57:54 +0100" MODIFIED_BY="Narelle Willis" REVIEW_NO="163" REVMAN_SUB_VERSION="5.2.6 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2013-08-07 08:46:59 +1000" MODIFIED_BY="Narelle Willis">
<TITLE>Interventions for erythropoietin-resistant anaemia in dialysis patients</TITLE>
<CONTACT>
<PERSON ID="0507341D82E26AA200492FF11FE55613" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Sunil</FIRST_NAME>
<MIDDLE_INITIALS>V</MIDDLE_INITIALS>
<LAST_NAME>Badve</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant Nephrologist</POSITION>
<EMAIL_1>sunil_badve@health.qld.gov.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Nephrology</DEPARTMENT>
<ORGANISATION>Princess Alexandra Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Woolloongabba</CITY>
<ZIP>4102</ZIP>
<REGION>QLD</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2013-08-07 08:46:59 +1000" MODIFIED_BY="Narelle Willis">
<PERSON ID="0507341D82E26AA200492FF11FE55613" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Sunil</FIRST_NAME>
<MIDDLE_INITIALS>V</MIDDLE_INITIALS>
<LAST_NAME>Badve</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant Nephrologist</POSITION>
<EMAIL_1>sunil_badve@health.qld.gov.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Nephrology</DEPARTMENT>
<ORGANISATION>Princess Alexandra Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Woolloongabba</CITY>
<ZIP>4102</ZIP>
<REGION>QLD</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="17287" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Elaine</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Beller</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Professor (Biostatistics)</POSITION>
<EMAIL_1>ebeller@bond.edu.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Faculty of Health Sciences and Medicine</DEPARTMENT>
<ORGANISATION>Bond University</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Gold Coast</CITY>
<ZIP>4229</ZIP>
<REGION>QLD</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 7 5595 5523</PHONE_1>
<PHONE_2/>
<FAX_1>+61 7 5595 1652</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7D5C559D82E26AA200EEC35C05F16DA5" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Alan</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Cass</LAST_NAME>
<SUFFIX/>
<POSITION>Co-Director</POSITION>
<EMAIL_1>acass@georgeinstitute.org.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Renal and Metabolic Division</DEPARTMENT>
<ORGANISATION>The George Institute for Global Health</ORGANISATION>
<ADDRESS_1>Level 10, King George V Building</ADDRESS_1>
<ADDRESS_2>Royal Prince Alfred Hospital</ADDRESS_2>
<CITY>Camperdown</CITY>
<ZIP>2050</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 2 99934553</PHONE_1>
<PHONE_2/>
<FAX_1>+61 2 99934502</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12260" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Daniel</FIRST_NAME>
<MIDDLE_INITIALS>P</MIDDLE_INITIALS>
<LAST_NAME>Francis</LAST_NAME>
<SUFFIX/>
<POSITION>Epidemiologist</POSITION>
<EMAIL_1>Daniel_Francis@health.qld.gov.au</EMAIL_1>
<EMAIL_2>danfrancis79@hotmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Central Regional Services, Division of the CHO</DEPARTMENT>
<ORGANISATION>Queensland Health</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Stafford DC</CITY>
<ZIP>4053</ZIP>
<REGION>QLD</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="FF77134D82E26AA200492FF1A372907C" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Carmel</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Hawley</LAST_NAME>
<SUFFIX/>
<POSITION>Director</POSITION>
<EMAIL_1>carmel_hawley@health.qld.gov.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Nephrology</DEPARTMENT>
<ORGANISATION>Princess Alexandra Hospital</ORGANISATION>
<ADDRESS_1>Ipswich Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Woolloongabba</CITY>
<ZIP>4102</ZIP>
<REGION>QLD</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 7 32405080</PHONE_1>
<PHONE_2/>
<FAX_1>+61 7 32405480</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="79148069266645467751090729032842" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Iain</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Macdougall</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>Iain.macdougall@nhs.net</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Renal Unit</DEPARTMENT>
<ORGANISATION>King's College Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>SE5 9RS</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 203 29999000 ext 6953</PHONE_1>
<PHONE_2/>
<FAX_1>+44 207 3466472</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="19789" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>Vlado</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Perkovic</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Professor</POSITION>
<EMAIL_1>vperkovic@georgeinstitute.org.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Renal and Metabolic Division</DEPARTMENT>
<ORGANISATION>The George Institute for Global Health</ORGANISATION>
<ADDRESS_1>Level 10, King George V Building</ADDRESS_1>
<ADDRESS_2>Royal Prince Alfred Hospital</ADDRESS_2>
<CITY>Camperdown</CITY>
<ZIP>2050</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 2 99934551</PHONE_1>
<PHONE_2/>
<FAX_1>+61 2 99934502</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="16113" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>David</FIRST_NAME>
<MIDDLE_INITIALS>W</MIDDLE_INITIALS>
<LAST_NAME>Johnson</LAST_NAME>
<SUFFIX/>
<POSITION>Nephrologist</POSITION>
<EMAIL_1>david_johnson@health.qld.gov.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Nephrology</DEPARTMENT>
<ORGANISATION>Princess Alexandra Hospital</ORGANISATION>
<ADDRESS_1>Ipswich Rd</ADDRESS_1>
<ADDRESS_2/>
<CITY>Woolloongabba</CITY>
<ZIP>4102</ZIP>
<REGION>QLD</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 7 3240 5080</PHONE_1>
<PHONE_2/>
<FAX_1>+61 7 3240 5480</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2013-04-18 17:17:58 +1000" MODIFIED_BY="Sunil Badve">
<UP_TO_DATE>
<DATE DAY="4" MONTH="4" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="4" MONTH="4" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="4" MONTH="10" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2010"/>
</DATES>
<WHATS_NEW MODIFIED="2013-04-18 17:17:25 +1000" MODIFIED_BY="[Empty name]"/>
<HISTORY/>
<SOURCES_OF_SUPPORT MODIFIED="2010-04-23 12:47:48 +1000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2010-04-23 12:47:48 +1000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2010-04-23 12:47:48 +1000" MODIFIED_BY="[Empty name]">
<NAME>Australasian Kidney Trials Network, School of Medicine, University of Queensland</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2009-05-27 14:51:35 +1000" MODIFIED_BY="[Empty name]">
<NAME>Princess Alexandra Hospital, Woolloongabba, QLD</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-08-07 08:48:29 +1000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-08-06 13:43:18 +1000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2013-08-06 11:58:09 +1000" MODIFIED_BY="[Empty name]">Interventions for anaemia in dialysis patients who are resistant to erythropoietin</TITLE>
<SUMMARY_BODY MODIFIED="2013-08-06 13:43:18 +1000" MODIFIED_BY="[Empty name]">
<P>Many people with chronic kidney disease (CKD) who are on dialysis develop anaemia (too few or poor quality red blood cells). Drugs in the erythropoiesis-stimulating family increase the production of red blood cells to resolve anaemia. Although ESAs have been highly beneficial for many, about 10% of people get either low or no benefit from treatment. Inability to control and stabilise anaemia can lead to poor rates of survival and increased risk of stroke so it is important to find effective treatment to manage anaemia in people who do not respond adequately to ESA therapy.</P>
<P>We searched the literature to find evidence about how best to treat people who do not benefit from ESA treatment. We found two studies: one that assessed intravenous vitamin C and another that looked at high-flux dialyser fluids as possible therapies. These studies were small (total of 90 participants) and were selective: they included haemodialysis, but not peritoneal dialysis, patients. This meant that the results of these studies could not be applied to all people with CKD on dialysis who were receiving ESA therapy. The lack of evidence meant that we could not determine or recommend an alternate treatment for people who do not respond to ESA.</P>
<P>More powerful and rigorous studies are needed to systematically assess all therapies that are aimed to treat people who do not respond to ESA therapy. Until such evidence is available, no therapy can be confidently recommended for this problem.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-08-07 08:46:59 +1000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-02-07 15:21:23 +1100" MODIFIED_BY="[Empty name]">
<P>People living with end-stage kidney disease (ESKD) often develop anaemia. Erythropoiesis-simulating agents (ESAs) are often given to people living with ESKD to maintain haemoglobin at a level to minimise need for transfusion. However, about 5% to 10% of patients with ESKD exhibit resistance to ESAs, and observational studies have shown that patients requiring high doses of ESA are at increased risk of mortality.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-02-06 15:19:06 +1100" MODIFIED_BY="[Empty name]">
<P>This review aimed to study the effects of interventions for the treatment of ESA-resistant anaemia in people with ESKD.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-08-07 08:46:59 +1000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE for randomised controlled trials (RCT) that involved participants with ESKD on dialysis or who were pre-dialysis patients with chronic kidney disease (stage 5). Date of last search: April 2013.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-08-01 17:11:47 +1000" MODIFIED_BY="[Empty name]">
<P>ESA resistance was defined as failure to achieve or maintain haemoglobin/haematocrit levels within the desired target range despite appropriate ESA doses (erythropoietin &#8805; 450 U/kg/wk intravenously or &#8805; 300 U/kg/wk subcutaneously; darbepoetin &#8805; 1.5 µg/kg/wk) in people who were not nutritionally deficient, or who had haematological or bleeding disorders. Extended inclusion criteria for ESA hyporesponsive state were: erythropoietin dose &#8805; 300 U/kg/wk and &#8805; 150 U/kg/wk for intravenous administration; or &#8805; 200 U/kg/wk and &#8805; 100 U/kg/wk for subcutaneous administration; or darbepoetin dose &#8805; 1.0 µg/kg/wk).</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-08-07 08:46:59 +1000" MODIFIED_BY="[Empty name]">
<P>Two authors independently assessed study quality and extracted data. Statistical analyses were performed using a random effects model and results expressed as risk ratio (RR) or mean difference (MD) with 95% confidence intervals (CI).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-08-07 08:46:59 +1000" MODIFIED_BY="[Empty name]">
<P>Titles and abstracts of 521 records were screened, of which we reviewed 99 from the full text. Only two studies matched our inclusion criteria. One study compared intravenous vitamin C versus no study medication for six months in 42 ESKD patients on haemodialysis who required intravenous erythropoietin (dose &#8805; 450 U/kg/wk). The other included study compared high-flux dialyser versus low-flux dialyser for six months in 48 haemodialysis patients who required subcutaneous erythropoietin (dose &#8805; 200 U/kg/wk). Because interventions differed, data could not be combined for quantitative meta-analysis.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-02-07 11:26:26 +1100" MODIFIED_BY="[Empty name]">
<P>There was inadequate evidence identified to inform recommendation of any intervention to ameliorate ESA hyporesponsiveness. Adequately powered RCTs are required to establish the safety and efficacy of interventions to improve responsiveness to ESA therapy.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-08-07 08:48:29 +1000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-08-07 08:48:29 +1000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2013-08-07 08:48:29 +1000" MODIFIED_BY="[Empty name]">
<P>Erythropoiesis-stimulating agents (ESAs) are perhaps the most rigorously tested group of drugs in nephrology. Since the introduction of ESAs, there have been substantial reductions in blood transfusion requirements among patients living with chronic kidney disease (CKD) (<LINK REF="REF-Eschbach-1989" TYPE="REFERENCE">Eschbach 1989</LINK>).</P>
<P>A systematic review of 14 randomised controlled and uncontrolled trials in pre-dialysis CKD patients demonstrated that treatment of anaemia with ESAs improved energy levels and physical function (<LINK REF="REF-Gandra-2010" TYPE="REFERENCE">Gandra 2010</LINK>). Unfortunately, a considerable proportion of these patients exhibited suboptimal haematologic response to ESA (<LINK REF="REF-Benz-1999" TYPE="REFERENCE">Benz 1999</LINK>; <LINK REF="REF-Valderrabano-1996" TYPE="REFERENCE">Valderrabano 1996</LINK>).</P>
<P>There are several known causes of suboptimal response to ESA. These include deficiencies in iron, vitamin B<SUB>12</SUB>, and folate; infection, chronic inflammatory state, neoplasia, severe hyperparathyroidism, aluminium intoxication, inadequate dialysis, myelosuppressive agents, haemoglobinopathies, myelodysplasia and antibody-mediated pure red cell aplasia (<LINK REF="REF-Macdougall-2002" TYPE="REFERENCE">Macdougall 2002</LINK>). However, after excluding these conditions it was found that about 10% of patients exhibit ESA-resistant anaemia, and these people have greatly increased rates of morbidity and mortality (<LINK REF="REF-Kausz-2005" TYPE="REFERENCE">Kausz 2005</LINK>; <LINK REF="REF-Macdougall-2002" TYPE="REFERENCE">Macdougall 2002</LINK>; <LINK REF="REF-Zhang-2004" TYPE="REFERENCE">Zhang 2004</LINK>).</P>
<P>ESA treatment used to target high haemoglobin levels in people with CKD is associated with deleterious (<LINK REF="REF-Phrommintikul-2007" TYPE="REFERENCE">Phrommintikul 2007</LINK>) or neutral (<LINK REF="REF-Palmer-2010" TYPE="REFERENCE">Palmer 2010</LINK>) impacts on survival and increased risks of stroke, vascular access thrombosis and hypertension without any reduction in cardiovascular events (<LINK REF="REF-Palmer-2010" TYPE="REFERENCE">Palmer 2010</LINK>; <LINK REF="REF-Phrommintikul-2007" TYPE="REFERENCE">Phrommintikul 2007</LINK>).</P>
<P>Although RCTs and systematic reviews consistently show more harm than benefit associated with higher haemoglobin targets for ESA treatment (<LINK REF="REF-Besarab-1998" TYPE="REFERENCE">Besarab 1998</LINK>; <LINK REF="REF-Palmer-2010" TYPE="REFERENCE">Palmer 2010</LINK>; <LINK REF="REF-Pfeffer-2009" TYPE="REFERENCE">Pfeffer 2009</LINK>; <LINK REF="REF-Phrommintikul-2007" TYPE="REFERENCE">Phrommintikul 2007</LINK>; <LINK REF="REF-Singh-2006" TYPE="REFERENCE">Singh 2006</LINK>), secondary analyses of RCTs and observational studies have demonstrated that poor response to ESA treatment rather than achieved high haemoglobin, may be responsible for the observed suboptimal outcomes in people with CKD (<LINK REF="REF-Kilpatrick-2008" TYPE="REFERENCE">Kilpatrick 2008</LINK>; <LINK REF="REF-Messana-2009" TYPE="REFERENCE">Messana 2009</LINK>; <LINK REF="REF-Regidor-2006" TYPE="REFERENCE">Regidor 2006</LINK>; <LINK REF="REF-Solomon-2010" TYPE="REFERENCE">Solomon 2010</LINK>; <LINK REF="REF-Szczech-2008" TYPE="REFERENCE">Szczech 2008</LINK>).</P>
<P>These studies also showed that patients who required higher doses of ESA experienced increased mortality at any haemoglobin level, and that patients who achieve target haemoglobin levels had better outcomes than those who did not (<LINK REF="REF-Badve-2011" TYPE="REFERENCE">Badve 2011</LINK>). Therefore, therapies targeting ESA resistance could be a promising treatment strategy in CKD anaemia management.</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-02-07 11:31:03 +1100" MODIFIED_BY="[Empty name]">
<P>Although there is no effective treatment for patients with ESA-resistant anaemia at present, a number of interventions such as L-carnitine, ascorbic acid, oxpentifylline, androgens and statins have been investigated.</P>
</INTERVENTION>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-08-01 17:22:28 +1000" MODIFIED_BY="Narelle S Willis">
<P>This review looked at the benefits and harms of any intervention used in the treatment of ESA-resistant anaemia in people with end-stage kidney disease (ESKD) who were receiving dialysis.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-08-07 08:47:43 +1000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-08-07 08:47:43 +1000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-02-07 11:33:21 +1100" MODIFIED_BY="[Empty name]">
<P>All randomised controlled trials (RCTs) and quasi-RCTs (studies in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) looking at interventions for the treatment of ESA-resistant anaemia in people with ESKD were included in our review.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-08-07 08:47:43 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Adults and children with ESKD (chronic kidney disease (CKD) stage 5 or pre-dialysis) or those receiving dialysis (either haemodialysis or peritoneal dialysis).</LI>
<LI>Adults and children with ESKD receiving any type of ESA for anaemia (anaemia defined as haemoglobin &lt; 110 g/L or as defined by the investigators).</LI>
<LI>Evidence of ESA resistance, defined as failure to achieve or maintain target range haemoglobin/haematocrit levels in spite of appropriate ESA doses (erythropoietin &#8805; 450 U/kg/wk intravenous administration or &#8805; 300 U/kg/wk for subcutaneous administration or darbepoetin &#8805; 1.5 µg/kg/wk) (<LINK REF="REF-KDOQI-2001" TYPE="REFERENCE">KDOQI 2001</LINK>; <LINK REF="REF-Locatelli-2004" TYPE="REFERENCE">Locatelli 2004</LINK>). This inclusion criterion was amended after publication of the protocol of this systematic review because only one eligible study was found. Extended inclusion criteria were studies that defined ESA-hyporesponsive state as failure to achieve or maintain target haemoglobin/haematocrit in spite of the following doses of the ESA: erythropoietin dosage &#8805; 300 and &#8805;150 U/kg/wk for IV administration; or &#8805; 200 and &#8805;100 U/kg/wk for subcutaneous administration; or darbepoetin dosage &#8805; 1.0 µg/kg/wk).</LI>
<LI>All known causes of ESA-resistance (such as iron deficiency, vitamin B<SUB>12</SUB> deficiency, folate deficiency, infection, chronic inflammatory state, neoplasia, severe hyperparathyroidism, aluminium intoxication, inadequate dialysis, myelosuppressive agents, haemoglobinopathies, myelodysplasia and antibody-mediated pure red cell aplasia) must have been ruled out.</LI>
<LI>Studies performed in kidney transplant recipients were excluded.</LI>
</UL>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-02-06 15:08:53 +1100" MODIFIED_BY="[Empty name]">
<P>Any potential intervention used to treat ESA-resistance, such as L-carnitine, ascorbic acid, oxpentifylline, androgens, and statins, were included in this review.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-02-07 11:36:35 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>All-cause mortality</LI>
<LI>Cardiovascular mortality</LI>
<LI>Non-fatal cardiovascular events</LI>
<LI>Number of patients achieving target haemoglobin/haematocrit</LI>
<LI>Difference or changes in haemoglobin or haematocrit between intervention and control groups at study end</LI>
<LI>Difference or changes in ESA dose between intervention and control groups at study end</LI>
<LI>Blood transfusion requirements</LI>
<LI>Quality of life</LI>
<LI>Hospitalisation</LI>
<LI>Any reported adverse events</LI>
<LI>Differences or changes in inflammatory biomarkers between intervention and control groups at study end</LI>
<LI>Differences or changes in biomarkers of oxidative stress between intervention and control groups at study end.</LI>
</UL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-08-07 08:46:59 +1000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2013-08-06 13:45:45 +1000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Renal Group's specialised register 18th March 2013 through contact with the Trials' Search Co-ordinator using search terms relevant to this review.</P>
<P>The Cochrane Renal Group&#8217;s Specialised Register contains studies identified from:</P>
<OL>
<LI>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</LI>
<LI>Weekly searches of MEDLINE OVID SP</LI>
<LI>Handsearching of renal-related journals and the proceedings of major renal conferences</LI>
<LI>Searching of the current year of EMBASE OVID SP</LI>
<LI>Weekly current awareness alerts for selected renal journals</LI>
<LI>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</LI>
</OL>
<P>Studies contained in the specialised register are identified through search strategies for CENTRAL, MEDLINE and EMBASE based on the scope of the Cochrane Renal Group. Details of these strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts, are available in the specialised register section of information about the <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html">Cochrane Renal Group</A>.</P>
<P>See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for search terms used in strategies for this review.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-08-07 08:46:59 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Reference lists of clinical practice guidelines, review articles and relevant studies.</LI>
<LI>Relevant missing or incomplete or unpublished data from the clinical studies were requested from the respective investigators/ authors by written correspondence.</LI>
</OL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-08-01 17:34:40 +1000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2013-08-01 17:10:16 +1000" MODIFIED_BY="[Empty name]">
<P>The search strategy described was used to obtain titles and abstracts of studies relevant to the review. Titles and abstracts were screened independently by three authors, who discarded studies that were not applicable. However, studies and reviews that potentially included relevant data or study information were retained initially. The same three authors independently assessed retrieved abstracts, and if necessary the full text, of these studies to determine which studies satisfied the inclusion criteria.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-08-01 17:10:11 +1000" MODIFIED_BY="[Empty name]">
<P>Data extraction was carried out independently by two authors using standard data extraction forms. Studies reported in non-English language journals was to be translated before assessment. Where more than one publication of one study existed, reports were grouped together and the publication with the most complete data was used in the analyses. Where relevant outcomes were only published in earlier versions, these data were used. Any discrepancies between published versions was to be highlighted. Disagreements were resolved by consensus.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-02-06 16:18:18 +1100" MODIFIED_BY="[Empty name]">
<P>The following items will be independently assessed by two authors using the risk of bias assessment tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) (see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>).</P>
<UL>
<LI>Was there adequate sequence generation (selection bias)?</LI>
<LI>Was allocation adequately concealed (selection bias)?</LI>
<LI>Was knowledge of the allocated interventions adequately prevented during the study (detection bias)?</LI>
<UL>
<LI>Participants and personnel</LI>
<LI>Outcome assessors</LI>
</UL>
<LI>Were incomplete outcome data adequately addressed (attrition bias)?</LI>
<LI>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)?</LI>
<LI>Was the study apparently free of other problems that could put it at a risk of bias?</LI>
</UL>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-02-06 16:09:27 +1100" MODIFIED_BY="[Empty name]">
<P>For dichotomous outcomes (all-cause mortality, cardiovascular mortality, non-fatal cardiovascular events, number of patients achieving haemoglobin/haematocrit targets, number of patients requiring hospitalisation, number of patients requiring blood transfusions, number of patients with medication-related adverse effects), results were expressed as risk ratios (RR) with 95% confidence intervals (CI). For continuous data (haemoglobin, haematocrit, iron studies, ESA dosage, iron dosage, hospitalisation days, quality of life scores, inflammatory biomarkers, biomarkers of oxidative stress), results were expressed as mean difference (MD).</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2013-08-01 17:10:01 +1000" MODIFIED_BY="[Empty name]">
<P>We planned that any further information required from the original author was to be requested by written correspondence, and any relevant information obtained was be included in the review. Evaluation of important numerical data such as screened, randomised patients as well as intention-to-treat (ITT), as-treated and per-protocol (PP) population was performed. </P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-08-01 17:34:40 +1000" MODIFIED_BY="[Empty name]">
<P>Heterogeneity was to be analysed using a Chi² test on N-1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I² test (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). I² values of 25%, 50% and 75% correspond to low, medium and high levels of heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-08-01 17:34:30 +1000" MODIFIED_BY="[Empty name]">
<P>Data were to be pooled using the random-effects model.</P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-08-07 08:46:59 +1000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-08-07 08:46:59 +1000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2013-08-01 18:30:47 +1000" MODIFIED_BY="Narelle S Willis">
<P>We identified 533 abstracts using the search strategy described (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). After screening titles and abstracts, 99 reports were selected for full text review. Only two studies (<LINK REF="STD-Attallah-2006" TYPE="STUDY">Attallah 2006</LINK>; <LINK REF="STD-Ayli-2004" TYPE="STUDY">Ayli 2004</LINK>) met our inclusion criteria, and of these, one investigated our extended inclusion criterion of ESA hyporesponsive state (<LINK REF="STD-Ayli-2004" TYPE="STUDY">Ayli 2004</LINK>).</P>
<P>We considered inclusion of a study that applied our extended inclusion criterion of ESA-hyporesponsive state (<LINK REF="STD-Sezer-2002" TYPE="STUDY">Sezer 2002</LINK>). In this study, participants in both arms received the investigational drug (vitamin C) in the first study phase (eight weeks). Non-responders were excluded at the end of the first phase. During the second phase, remaining participants were randomised to receive either the investigational drug at a reduced frequency or no study drug for another eight weeks. Since the investigators did not define 'non-responder', and there was a strong possibility of carry over effect of vitamin C administered before randomisation, the study was excluded from this systematic review.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-08-07 08:46:59 +1000" MODIFIED_BY="Narelle S Willis">
<P>Two studies met our inclusion criteria.</P>
<UL>
<LI>
<LINK REF="STD-Attallah-2006" TYPE="STUDY">Attallah 2006</LINK> enrolled 42 haemodialysis patients and compared IV vitamin C given at each dialysis session to no treatment.</LI>
<LI>
<LINK REF="STD-Ayli-2004" TYPE="STUDY">Ayli 2004</LINK> enrolled 48 haemodialysis patients and compared high-flux versus low-flux dialysis membranes</LI>
</UL>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-08-07 08:46:59 +1000" MODIFIED_BY="Narelle S Willis">
<P>We excluded 68 studies after full-text review: six were not randomised; 58 included participants who did not have ESA resistance; two included iron deficient participants who lacked true ESA resistance; and two studies did not use ESA in the control arm.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-08-01 17:38:31 +1000" MODIFIED_BY="[Empty name]">
<ALLOCATION MODIFIED="2013-02-07 11:47:39 +1100" MODIFIED_BY="[Empty name]">
<P>Allocation concealment was unclear in both included studies (<LINK REF="STD-Attallah-2006" TYPE="STUDY">Attallah 2006</LINK>; <LINK REF="STD-Ayli-2004" TYPE="STUDY">Ayli 2004</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-08-01 17:37:22 +1000" MODIFIED_BY="[Empty name]">
<P>It was unclear if in <LINK REF="STD-Attallah-2006" TYPE="STUDY">Attallah 2006</LINK>, an open-label study, outcome assessors were blinded. Likewise, blinding of participants, investigators or outcome assessors in <LINK REF="STD-Ayli-2004" TYPE="STUDY">Ayli 2004</LINK> was also unclear.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-08-01 17:37:42 +1000" MODIFIED_BY="[Empty name]">
<P>All participants were followed for the entire study period and accounted for in both studies. Attrition bias arising from incomplete outcome reporting was deemed to be low risk.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-08-01 17:38:03 +1000" MODIFIED_BY="[Empty name]">
<P>Neither study reported proportions of participants in each study arm who achieved haemoglobin target levels. The risk of reporting bias in both was therefore unclear.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2013-08-01 17:38:31 +1000" MODIFIED_BY="[Empty name]">
<P>Both studies were judged to be at high risk of other potential sources of bias due to single-centre study design and exclusion of patients on peritoneal dialysis.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-08-06 14:18:37 +1000" MODIFIED_BY="[Empty name]">
<P>Treatments differed in the interventional arms of <LINK REF="STD-Attallah-2006" TYPE="STUDY">Attallah 2006</LINK> and <LINK REF="STD-Ayli-2004" TYPE="STUDY">Ayli 2004</LINK> (vitamin C and high-flux dialyser). Therefore, data were not combined and results are presented separately.</P>
<SUBSECTION>
<HEADING LEVEL="3">Clinical outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">All-cause and cardiovascular mortality</HEADING>
<P>No deaths were reported in either study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Non-fatal cardiovascular events</HEADING>
<P>
<LINK REF="STD-Attallah-2006" TYPE="STUDY">Attallah 2006</LINK> reported no significant difference in the risk of non-fatal cardiovascular events between study arms (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>: RR 0.79, 95% CI 0.20 to 3.09).</P>
<P>
<LINK REF="STD-Ayli-2004" TYPE="STUDY">Ayli 2004</LINK> did not report non-fatal cardiovascular events.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants achieving target haemoglobin or haematocrit</HEADING>
<P>Neither study reported the proportions of participants who achieved target haemoglobin or haematocrit levels.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Requirement of blood transfusions</HEADING>
<P>
<LINK REF="STD-Attallah-2006" TYPE="STUDY">Attallah 2006</LINK> reported no participants included in the final analysis required blood transfusion. However, one participant from the control group was excluded from the final analysis because of the need for a blood transfusion due to a significant upper gastrointestinal bleed.</P>
<P>
<LINK REF="STD-Ayli-2004" TYPE="STUDY">Ayli 2004</LINK> did not report need for blood transfusion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Hospitalisations</HEADING>
<P>
<LINK REF="STD-Attallah-2006" TYPE="STUDY">Attallah 2006</LINK> reported no significant difference in the risk of hospitalisations between the groups (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>: RR 0.96, 95% CI 0.56 to 1.66).</P>
<P>
<LINK REF="STD-Ayli-2004" TYPE="STUDY">Ayli 2004</LINK> did not report hospitalisations.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Medication-related adverse events</HEADING>
<P>
<LINK REF="STD-Attallah-2006" TYPE="STUDY">Attallah 2006</LINK> reported there were no adverse events noted in either group. <LINK REF="STD-Ayli-2004" TYPE="STUDY">Ayli 2004</LINK> did not report adverse events.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Haematology and biochemistry results</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Haemoglobin</HEADING>
<P>Both studies reported significantly higher haemoglobin levels in the treatment groups compared to the control groups (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>.1: MD 0.9 g/dL, 95% CI 0.38 to 1.42; <LINK REF="STD-Attallah-2006" TYPE="STUDY">Attallah 2006</LINK>); (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>.2: MD 1.9 g/dL, 95% CI 1.64 to 2.16; <LINK REF="STD-Ayli-2004" TYPE="STUDY">Ayli 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Haematocrit</HEADING>
<P>
<LINK REF="STD-Attallah-2006" TYPE="STUDY">Attallah 2006</LINK> did not report data on participants' haematocrit levels. <LINK REF="STD-Ayli-2004" TYPE="STUDY">Ayli 2004</LINK> reported that among interventional arm participants haematocrit was significantly higher than those in the control arm (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>: MD 6.8%, 95% CI 5.67 to 7.93).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Transferin saturation (TSAT)</HEADING>
<P>
<LINK REF="STD-Attallah-2006" TYPE="STUDY">Attallah 2006</LINK> reported that TSAT was significantly higher in interventional than control arm participants (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>.1: MD 8.00%, 95% CI 6.22 to 9.78). There was no significant difference in TSAT between study arms reported by <LINK REF="STD-Ayli-2004" TYPE="STUDY">Ayli 2004</LINK> (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>.2: MD 1.30%, 95% CI -3.99 to 6.59).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Ferritin</HEADING>
<P>
<LINK REF="STD-Attallah-2006" TYPE="STUDY">Attallah 2006</LINK> reported that ferritin was significantly higher among interventional than control arm participants (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>.1: MD 8.00 ng/mL, 95% CI -85.51 to 101.51). There was no significant difference between study arms reported by <LINK REF="STD-Ayli-2004" TYPE="STUDY">Ayli 2004</LINK> (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>.2: MD -3.00 ng/mL, 95% CI -43.46 to 37.46).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Haemoglobin content in reticulocytes (CHr)</HEADING>
<P>
<LINK REF="STD-Attallah-2006" TYPE="STUDY">Attallah 2006</LINK> reported that CHr was significantly higher in interventional than control arm participants (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>: MD 0.90 pg, 95% CI 0.40 to 1.40). <LINK REF="STD-Ayli-2004" TYPE="STUDY">Ayli 2004</LINK> did not report CHr data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Inflammatory biomarkers: C-reactive protein</HEADING>
<P>
<LINK REF="STD-Attallah-2006" TYPE="STUDY">Attallah 2006</LINK> reported C-reactive protein was significantly lower in vitamin C group compared to the control group (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>.1: MD -1.20 mg/dL, 95% CI -1.69 to -0.71). There was no significant difference between study arms in C-reactive protein reported by <LINK REF="STD-Ayli-2004" TYPE="STUDY">Ayli 2004</LINK> (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>.2: MD -0.4 mg/dL, 95% CI -3.0 to 2.2).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Markers of oxidative stress</HEADING>
<P>Neither <LINK REF="STD-Attallah-2006" TYPE="STUDY">Attallah 2006</LINK> nor <LINK REF="STD-Ayli-2004" TYPE="STUDY">Ayli 2004</LINK> reported markers of oxidative stress.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">ESA and intravenous iron doses</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">ESA dose</HEADING>
<P>
<LINK REF="STD-Attallah-2006" TYPE="STUDY">Attallah 2006</LINK> reported ESA was significantly lower in vitamin c group compared to the control group (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>: MD -18 U/kg/wk, 95% CI -35.62 to -0.38). <LINK REF="STD-Ayli-2004" TYPE="STUDY">Ayli 2004</LINK> did not report data on ESA dose.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Intravenous iron therapy dose</HEADING>
<P>
<LINK REF="STD-Attallah-2006" TYPE="STUDY">Attallah 2006</LINK> reported that there was no significant difference in intravenous iron therapy dose between the study arms (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>: MD -0.20 mg/wk, 95% CI -16.15 to 15.75). <LINK REF="STD-Ayli-2004" TYPE="STUDY">Ayli 2004</LINK> did not report on intravenous iron therapy dose.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Hospitalisation days</HEADING>
<P>Neither <LINK REF="STD-Attallah-2006" TYPE="STUDY">Attallah 2006</LINK> nor <LINK REF="STD-Ayli-2004" TYPE="STUDY">Ayli 2004</LINK> reported numbers of hospitalisation days.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Quality of life scores</HEADING>
<P>Neither <LINK REF="STD-Attallah-2006" TYPE="STUDY">Attallah 2006</LINK> nor <LINK REF="STD-Ayli-2004" TYPE="STUDY">Ayli 2004</LINK> reported quality of life scores.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-08-07 08:46:59 +1000" MODIFIED_BY="[Empty name]">
<P>The results of this systematic review highlight the absence of adequately powered randomised controlled trials (RCT) examining the effect of various interventions to treat ESA hyporesponsiveness. We found that there was insufficient and inadequate evidence to recommend any intervention to ameliorate ESA-hyporesponsiveness.</P>
<P>We identified only one RCT that defined ESA-hyporesponsiveness as intravenous EPO dose &#8805; 450 U/kg/wk (<LINK REF="STD-Attallah-2006" TYPE="STUDY">Attallah 2006</LINK>). When inclusion criteria were extended to include subcutaneous EPO dose &#8805; 200 U/kg/wk, another study, <LINK REF="STD-Ayli-2004" TYPE="STUDY">Ayli 2004</LINK>, was found to be eligible for inclusion.</P>
<P>In relation to intravenous vitamin C therapy, <LINK REF="STD-Attallah-2006" TYPE="STUDY">Attallah 2006</LINK> demonstrated increases in haemoglobin, haemoglobin content in reticulocytes, and transferin saturation; and reductions in erythropoietin dose and C-reactive protein. <LINK REF="STD-Ayli-2004" TYPE="STUDY">Ayli 2004</LINK> reported that use of high-flux dialyser for six months was associated with improvement in haemoglobin, but there was no effect on C-reactive protein or iron studies. Both <LINK REF="STD-Attallah-2006" TYPE="STUDY">Attallah 2006</LINK> and <LINK REF="STD-Ayli-2004" TYPE="STUDY">Ayli 2004</LINK> were single-centre studies and included 42 and 48 participants respectively. The studies included only haemodialysis patients, and hence, results may not be generalisable to CKD patients not yet on dialysis, those on peritoneal dialysis, or in settings where patient populations differ.</P>
<P>There is no single widely accepted definition of ESA resistance. KDOQI has defined ESA resistance as failure to achieve haemoglobin 11 g/dL with ESA dose equivalent to epoetin greater than 500 IU/kg/wk (<LINK REF="REF-KDOQI-2006" TYPE="REFERENCE">KDOQI 2006</LINK>). Publication of KDIGO anaemia guidelines is expected this year. As yet, there have been no RCTs performed explicitly in patients with ESA resistance as defined by KDOQI.</P>
<P>In the Normal Haematocrit Cardiac Trial, more participants in the normal haematocrit group reached the primary endpoint (composite of death and non-fatal myocardial infarction) with mean erythropoietin doses of 440 IU/kg/wk, which is lower than the KDOQI definition (<LINK REF="REF-Besarab-1998" TYPE="REFERENCE">Besarab 1998</LINK>). In the CHOIR trial, it was reported that ESA dose &gt; 20,000 IU/wk was associated with increased risk of death, congestive heart failure, stroke, and myocardial infarction (<LINK REF="REF-Szczech-2008" TYPE="REFERENCE">Szczech 2008</LINK>).</P>
<P>Several observational studies have suggested a linear association between ESA dose and adverse outcomes (<LINK REF="REF-Brookhart-2010" TYPE="REFERENCE">Brookhart 2010</LINK>; <LINK REF="REF-Messana-2009" TYPE="REFERENCE">Messana 2009</LINK>; <LINK REF="REF-Regidor-2006" TYPE="REFERENCE">Regidor 2006</LINK>; <LINK REF="REF-Zhang-2004" TYPE="REFERENCE">Zhang 2004</LINK>; <LINK REF="REF-Zhang-2009" TYPE="REFERENCE">Zhang 2009</LINK>). There is substantial variability in the reporting of ESA dose, such as IU/kg/wk, IU/wk, or ESA dose normalised to haemoglobin level. Therefore, the current KDOQI definition of ESA resistance needs to be revised, and the new definition should be based on ESA-resistance index (ERI) rather than ESA dose to bring uniformity in reporting.</P>
<P>The revised inclusion criteria of the ongoing <A HREF="https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82696">HERO Study</A> are ESA-resistance index &#8805; 1.0 IU/kg/wk/haemoglobin for epoetin-treated patients and &#8805; 0.005 µg/kg/wk/g haemoglobin for darbepoetin-treated patients (<LINK REF="STD-Johnson-2008" TYPE="STUDY">Johnson 2008</LINK>). <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> presents current definitions of ESA resistance.</P>
<P>An emerging body of evidence indicates more harm than benefit from targeting higher haemoglobin levels with ESA therapy. Patients who needed higher doses of ESA experienced increased mortality at any haemoglobin level, and patients who achieved target haemoglobin levels had better outcomes than those who did not.</P>
<P>Further RCTs are needed urgently to consider the clinical impacts of therapies purported to reduce ESA resistance.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-02-07 12:37:26 +1100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-02-07 12:36:17 +1100" MODIFIED_BY="[Empty name]">
<P>Based on two small, single-centre studies, there was inadequate evidence to recommend any intervention to ameliorate ESA-hyporesponsiveness.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-02-07 12:37:26 +1100" MODIFIED_BY="[Empty name]">
<P>Adequately powered multicentre RCTs involving a wide range of CKD patients receiving ESA therapy should be conducted as a priority. In addition to those on haemodialysis, future RCTs should include pre-dialysis CKD patients as well people receiving peritoneal dialysis. </P>
<P>Future studies should focus on true ESA responsiveness rather than a haemoglobin-targeted approach. Importantly, these studies should also include cost-effectiveness and economic analyses.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-02-06 16:30:44 +1100" MODIFIED_BY="[Empty name]">
<P>The authors would like to acknowledge Narelle Willis and Ruth Mitchell from the Cochrane Renal Group for their assistance. The authors would also like to thank the referees for their editorial advice during the preparation of this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-08-06 15:31:32 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Dr Sunil V Badve, Elaine Beller and Daniel P Francis have no conflicts of interest to declare.</LI>
<LI>Associate Professor Carmel Hawley has received consulting fees from Amgen and Janssen-Cilag; research grants from Amgen, Roche and Janssen-Cilag; and speakers&#8217; honoraria from Amgen.</LI>
<LI>Professor Alan Cass is the recipient of a NHMRC Senior Research Fellowship. He has received speaker's honoraria and research grants from Janssen-Cilag, Amgen and Roche.</LI>
<LI>Associate Professor Vlado Perkovic has received speakers&#8217; honoraria from Roche and research grants from Johnson and Johnson Pharmaceutical Research &amp; Development and Roche.</LI>
<LI>Professor Iain C. Macdougall has received consultant fees, research grants, and/or lecture fees from Amgen, Ortho biotech, Roche, Affymax, Takeda, Hospira, and Sandoz.</LI>
<LI>Professor David Johnson has received speakers' honoraria, consultancy fees and research grants from Janssen-Cilag, Amgen and Roche. He has received fees for organising education from Amgen and Janssen-Cilag. He has received consultancy fees from Pfizer. He is also the Principal Investigator in the HERO Trial, a randomised, double-blind, placebo-controlled trial of oxpentifylline in the treatment of erythropoietin stimulating agent hyporesponsiveness. Professor Alan Cass and Associate Professor Carmel Hawley are the members of the Trial Management Committee of the HERO trial.</LI>
</UL>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-08-01 17:08:16 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Write the protocol: SB, DF, EB, CH, DJ, IM, AC, VP</LI>
<LI>Study selection: SB, CH, DJ</LI>
<LI>Extract data from studies: SB, DJ</LI>
<LI>Enter data into RevMan: SB, DJ</LI>
<LI>Data analysis: SB, DF, EB</LI>
<LI>Interpret the analysis: SB, DJ</LI>
<LI>Draft the final review: SB, DJ</LI>
<LI>Disagreement resolution: DF, EB, CH, IM, AC, VP</LI>
<LI>Update the review: SB, DJ</LI>
</UL>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-08-06 15:32:00 +1000" MODIFIED_BY="[Empty name]">
<P>In the protocol for this review, we had planned that one of our inclusion criteria would define ESA resistance. Evidence of ESA-resistance, defined as failure to achieve or maintain target range haemoglobin/haematocrit levels in spite of appropriate doses of the ESA (erythropoietin dose &#8805; 450 U/kg/wk intravenous administration or &#8805; 300 U/kg/wk for subcutaneous administration or darbepoetin dosage &#8805; 1.5 µg/kg/wk) (<LINK REF="REF-KDOQI-2001" TYPE="REFERENCE">KDOQI 2001</LINK>; <LINK REF="REF-Locatelli-2004" TYPE="REFERENCE">Locatelli 2004</LINK>) was to be applied. This inclusion criterion was amended because only one eligible study was found.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-08-07 08:46:59 +1000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2013-08-07 08:46:59 +1000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-08-07 08:46:59 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Attallah-2006" MODIFIED="2013-08-01 16:37:37 +1000" MODIFIED_BY="[Empty name]" NAME="Attallah 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-04-18 17:36:57 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Attallah N, Osman-Malik Y, Adams B, Frinak S, Besarab A</AU>
<TI>Effect of intravenous ascorbic acid in hemodialysis patients with erythropoietin-hyporesponsive anemia and hyperferritenemia [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2005</YR>
<VL>16</VL>
<PG>488A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-08-01 16:37:37 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Attallah N, Osman-Malik Y, Frinak S, Besarab A</AU>
<TI>Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2006</YR>
<VL>47</VL>
<NO>4</NO>
<PG>644-54</PG>
<IDENTIFIERS MODIFIED="2013-08-01 16:37:37 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-08-01 16:37:37 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16564942"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-04-23 09:38:56 +1000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ayli-2004" MODIFIED="2013-08-07 08:46:59 +1000" MODIFIED_BY="[Empty name]" NAME="Ayli 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-08-01 16:41:34 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ayli D, Ayli M, Azak A, Yksel C, Kosmaz GP, Atilgan G, et al</AU>
<TI>The effect of high-flux hemodialysis on renal anemia</TI>
<SO>Journal of Nephrology</SO>
<YR>2004</YR>
<VL>17</VL>
<NO>5</NO>
<PG>701-6</PG>
<IDENTIFIERS MODIFIED="2013-08-01 16:41:34 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-08-01 16:41:34 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15593038"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-08-01 16:45:07 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ayli M, Ayli D, Azak A, Yuksel C, Atilgan G, Dede F, et al</AU>
<TI>The effect of high-flux hemodialysis on dialysis-associated amyloidosis</TI>
<SO>Renal Failure</SO>
<YR>2005</YR>
<VL>27</VL>
<NO>1</NO>
<PG>31-4</PG>
<IDENTIFIERS MODIFIED="2013-08-01 16:45:05 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2013-08-01 16:45:05 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="15717632"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-08-06 14:48:12 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abe-2010" MODIFIED="2013-04-18 17:34:41 +1000" MODIFIED_BY="[Empty name]" NAME="Abe 2010" YEAR="2010 Jul">
<REFERENCE MODIFIED="2013-01-30 17:44:08 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abe M, Okada K, Maruyama T, Maruyama N, Soma M, Matsumoto K</AU>
<TI>Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis</TI>
<SO>Expert Opinion on Pharmacotherapy</SO>
<YR>2010</YR>
<VL>11</VL>
<NO>10</NO>
<PG>1611-20</PG>
<IDENTIFIERS MODIFIED="2013-01-30 17:43:58 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="20540652"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Acchiardo-1989" MODIFIED="2013-08-01 16:02:43 +1000" MODIFIED_BY="[Empty name]" NAME="Acchiardo 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-08-01 16:02:43 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Acchiardo SR, Quinn BP, Burk LB, Moore LW</AU>
<TI>Are high flux dialysis and erythropoietin treatment in a collision course?</TI>
<SO>ASAIO Transactions</SO>
<YR>1989</YR>
<VL>35</VL>
<NO>3</NO>
<PG>308-10</PG>
<IDENTIFIERS MODIFIED="2013-08-01 16:01:57 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-08-01 16:01:57 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="2688711"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aliev-1997" MODIFIED="2013-08-06 14:38:38 +1000" MODIFIED_BY="[Empty name]" NAME="Aliev 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-08-06 14:38:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Aliev MA, Ismagilov RZ, Tsoy GM, Yusumbaeva AS</AU>
<TI>Influence of Eprex in combination with antihistamine drugs on correction of anemia in haemodialysis patients [abstract]</TI>
<SO>34th Congress European Renal Association/European Dialysis and Transplantation Association; Geneva, Switzerland</SO>
<YR>1997</YR>
<PG>236</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Andrulli-2010" MODIFIED="2013-08-01 16:03:24 +1000" MODIFIED_BY="[Empty name]" NAME="Andrulli 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-08-01 16:03:24 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andrulli S, Di Filippo S, Manzoni C, Stefanelli L, Floridi A, Galli F, et al</AU>
<TI>Effect of synthetic vitamin E-bonded membrane on responsiveness to erythropoiesis-stimulating agents in hemodialysis patients: a pilot study</TI>
<SO>Nephron</SO>
<YR>2010</YR>
<VL>115</VL>
<NO>1</NO>
<PG>c82-9</PG>
<IDENTIFIERS MODIFIED="2013-08-01 16:03:24 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-08-01 16:03:24 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="20215781"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-03-18 14:29:50 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-18 14:29:50 +1100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00687258"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ballal-1991" MODIFIED="2013-03-11 10:16:16 +1100" MODIFIED_BY="[Empty name]" NAME="Ballal 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-03-11 10:16:16 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ballal SH, Domoto DT, Polack DC, Marciulonis P, Martin KJ</AU>
<TI>Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1991</YR>
<VL>17</VL>
<NO>1</NO>
<PG>29-33</PG>
<IDENTIFIERS MODIFIED="2013-03-11 10:16:16 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-11 10:16:16 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="1986567"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barany-1998" MODIFIED="2013-04-18 17:37:37 +1000" MODIFIED_BY="[Empty name]" NAME="Barany 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-04-18 17:37:37 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barany P</AU>
<TI>Treatment of anemia in hemodialysis patients to a normal hemoglobin concentration - results of an open randomized clinical trial of epoetin beta [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1998</YR>
<VL>9</VL>
<PG>243A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berns-1992" MODIFIED="2013-03-11 10:33:14 +1100" MODIFIED_BY="[Empty name]" NAME="Berns 1992" YEAR="1992">
<REFERENCE MODIFIED="2013-03-11 10:33:14 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berns JS, Rudnick MR, Cohen RM</AU>
<TI>A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis</TI>
<SO>Clinical Nephrology</SO>
<YR>1992</YR>
<VL>37</VL>
<NO>5</NO>
<PG>264-7</PG>
<IDENTIFIERS MODIFIED="2013-03-11 10:33:14 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-11 10:33:14 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="1606777"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brockenbrough-2006" MODIFIED="2013-03-11 10:33:28 +1100" MODIFIED_BY="[Empty name]" NAME="Brockenbrough 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-03-11 10:33:28 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brockenbrough AT, Dittrich MO, Page ST, Smith T, Stivelman JC, Bremner WJ</AU>
<TI>Transdermal androgen therapy to augment EPO in the treatment of anemia of chronic renal disease</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2006</YR>
<VL>47</VL>
<NO>2</NO>
<PG>251-62</PG>
<IDENTIFIERS MODIFIED="2013-03-11 10:33:28 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-11 10:33:28 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16431254"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buchwald-1977" MODIFIED="2013-08-06 11:55:01 +1000" MODIFIED_BY="[Empty name]" NAME="Buchwald 1977" YEAR="1977">
<REFERENCE MODIFIED="2013-08-06 11:55:01 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buchwald D, Argyres S, Easterling RE, Oelshlegel FJ, Brewer GJ, Schoomaker EB, et al</AU>
<TI>Effect of nandrolone decanoate on the anemia of chronic hemodialysis patients</TI>
<SO>Nephron</SO>
<YR>1977</YR>
<VL>18</VL>
<NO>4</NO>
<PG>232-8</PG>
<IDENTIFIERS MODIFIED="2013-08-06 11:55:01 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-08-06 11:55:01 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE=" 323739"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cao-2010" MODIFIED="2013-08-01 16:04:20 +1000" MODIFIED_BY="[Empty name]" NAME="Cao 2010" YEAR="2010 Nov">
<REFERENCE MODIFIED="2013-08-01 16:04:20 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cao W, Liu JH, Zhang H, Zhang L, Zhang LY, Pan MM</AU>
<TI>Effect of acupoint injection on erythropoietin resistance in patients with chronic renal failure</TI>
<SO>Zhongguo Zhenjiu [Chinese Acupuncture &amp; Moxibustion]</SO>
<YR>2010</YR>
<VL>30</VL>
<NO>11</NO>
<PG>891-5</PG>
<IDENTIFIERS MODIFIED="2013-08-01 16:04:20 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-08-01 16:04:20 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="21246842"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caruso-1998" MODIFIED="2013-04-18 17:44:16 +1000" MODIFIED_BY="[Empty name]" NAME="Caruso 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-04-18 17:44:16 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caruso U, Leone L, Cravotto E, Nava D</AU>
<TI>Effects of L-carnitine on anemia in aged hemodialysis patients treated with recombinant human erythropoietin: A pilot study</TI>
<SO>Dialysis &amp; Transplantation</SO>
<YR>1998</YR>
<VL>27</VL>
<NO>8</NO>
<PG>498-506</PG>
<IDENTIFIERS MODIFIED="2013-03-11 10:38:43 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-11 10:38:43 +1100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="1998284168"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cerulli-2000" MODIFIED="2013-08-01 16:06:40 +1000" MODIFIED_BY="[Empty name]" NAME="Cerulli 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-08-01 16:06:40 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<TI>The effect of hemodiafiltration with on-line endogenous reinfusion (on-line HFR) on anemia: design of a European, open, randomised, multicentre trial. European Collaborative Study</TI>
<SO>Journal of Nephrology</SO>
<YR>2000</YR>
<VL>13</VL>
<NO>1</NO>
<PG>34-42</PG>
<IDENTIFIERS MODIFIED="2013-03-11 10:40:17 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-11 10:40:17 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10720212"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chan-2005" MODIFIED="2013-04-18 17:44:41 +1000" MODIFIED_BY="[Empty name]" NAME="Chan 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-03-11 10:42:52 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chan D, Irish A, Croft KD, Dogra G</AU>
<TI>Effect of ascorbic acid supplementation on plasma isoprostanes in haemodialysis patients</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>1</NO>
<PG>234-5</PG>
<IDENTIFIERS MODIFIED="2013-03-11 10:42:52 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-11 10:42:52 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16204285"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-04-18 17:44:41 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chan D, Irish A, Dogra G</AU>
<TI>Efficacy and safety of oral compared with intravenous ascorbic acid in improving anaemia in erythropoietin hyporesponsive, iron overloaded, haemodialysis patients - a randomised open-label study [abstract]</TI>
<SO>Nephrology</SO>
<YR>2003</YR>
<VL>8 Suppl 3</VL>
<PG>A80-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-11 10:41:51 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chan D, Irish A, Dogra G</AU>
<TI>Efficacy and safety of oral versus intravenous ascorbic acid for anaemia in haemodialysis patients</TI>
<SO>Nephrology</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>4</NO>
<PG>336-40</PG>
<IDENTIFIERS MODIFIED="2013-03-11 10:41:51 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-11 10:41:51 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16109077"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2003" MODIFIED="2013-04-18 17:34:51 +1000" MODIFIED_BY="[Empty name]" NAME="Chen 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-03-11 10:44:41 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen WT, Lin YF, Yu FC, Kao WY, Huang WH, Yan HC</AU>
<TI>Effect of ascorbic acid administration in hemodialysis patients on in vitro oxidative stress parameters: influence of serum ferritin levels</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2003</YR>
<VL>42</VL>
<NO>1</NO>
<PG>158-66</PG>
<IDENTIFIERS MODIFIED="2013-03-11 10:44:41 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-11 10:44:41 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12830468"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cruz-2008" MODIFIED="2013-08-06 14:46:32 +1000" MODIFIED_BY="[Empty name]" NAME="Cruz 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-08-06 14:46:32 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cruz DN, De Cal M, Garzotto F, Brendolan A, Nalesso F, Corradi V, et al</AU>
<TI>Effect of vitamin E-coated dialysis membranes on anemia in patients with chronic kidney disease: an Italian multicenter study</TI>
<SO>International Journal of Artificial Organs</SO>
<YR>2008</YR>
<VL>31</VL>
<NO>6</NO>
<PG>545-52</PG>
<IDENTIFIERS MODIFIED="2013-08-06 14:46:32 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-08-06 14:46:32 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18609507"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Culleton-2007" MODIFIED="2013-04-18 17:45:29 +1000" MODIFIED_BY="[Empty name]" NAME="Culleton 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-02-21 17:13:11 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Culleton BF, Walsh M, Klarenbach SW, Mortis G, Scott-Douglas N, Quinn RR, et al</AU>
<TI>Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2007</YR>
<VL>298</VL>
<NO>11</NO>
<PG>1291-9</PG>
<IDENTIFIERS MODIFIED="2013-02-21 17:13:11 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="17878421"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-04-18 17:45:04 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Culleton BF, Walsh M, Klarenbach SW, Mortis G, Scott-Douglas N, Quinn RR, et al</AU>
<TI>Nocturnal hemodialysis lowers blood pressure and reduces left ventricular mass: results of a randomized controlled trial [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>Abstracts</NO>
<PG>67A-8A</PG>
<IDENTIFIERS MODIFIED="2013-03-11 10:55:31 +1100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-11 10:55:41 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khangura J, Culleton BF, Manns BJ, Zhang J, Barnieh L, Walsh M, et al</AU>
<TI>Association between routine and standardized blood pressure measurements and left ventricular hypertrophy among patients on hemodialysis</TI>
<SO>BMC Nephrology</SO>
<YR>2010</YR>
<VL>11</VL>
<PG>13</PG>
<IDENTIFIERS MODIFIED="2013-03-11 10:55:41 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="20576127"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-04-18 17:45:17 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manns BJ, Klarenbach S, Walsh M, Quinn R, Tonelli M, Scott-Douglas N, et al</AU>
<TI>The impact of nocturnal hemodialysis on quality of life: results of a randomized controlled trial [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>Abstracts</NO>
<PG>298A-9A</PG>
<IDENTIFIERS MODIFIED="2013-03-11 10:55:49 +1100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-11 10:55:59 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manns BJ, Walsh MW, Culleton BF, Hemmelgarn B, Tonelli M, Schorr M, et al</AU>
<TI>Nocturnal hemodialysis does not improve overall measures of quality of life compared to conventional hemodialysis</TI>
<SO>Kidney International</SO>
<YR>2009</YR>
<VL>75</VL>
<NO>5</NO>
<PG>542-9</PG>
<IDENTIFIERS MODIFIED="2013-03-11 10:55:59 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="19109588"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-11 10:56:07 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schorr M, Manns BJ, Culleton B, Walsh M, Klarenbach S, Tonelli M, et al</AU>
<TI>The effect of nocturnal and conventional hemodialysis on markers of nutritional status: results from a randomized trial</TI>
<SO>Journal of Renal Nutrition</SO>
<YR>2011</YR>
<VL>21</VL>
<NO>3</NO>
<PG>271-6</PG>
<IDENTIFIERS MODIFIED="2013-03-11 10:56:07 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="20650654"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-04-18 17:45:29 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Walsh M, Manns B, Tonelli M, Quinn R, Culleton B</AU>
<TI>Description of a randomized controlled trial on the effects of nocturnal hemodialysis on left ventricular hypertrophy compared to conventional hemodialysis [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2005</YR>
<VL>16</VL>
<PG>734A-5A</PG>
<IDENTIFIERS MODIFIED="2013-03-11 10:56:19 +1100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-11 10:56:28 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Walsh M, Manns BJ, Klarenbach S, Quinn R, Tonelli M, Culleton BF</AU>
<TI>The effects of nocturnal hemodialysis compared to conventional hemodialysis on change in left ventricular mass: rationale and study design of a randomized controlled pilot study</TI>
<SO>BMC Nephrology</SO>
<YR>2006</YR>
<VL>7</VL>
<PG>2</PG>
<IDENTIFIERS MODIFIED="2013-03-11 10:56:28 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="16504054"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-11 10:58:01 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Walsh M, Manns BJ, Klarenbach S, Tonelli M, Hemmelgarn B, Culleton B</AU>
<TI>The effects of nocturnal compared with conventional hemodialysis on mineral metabolism: a randomized-controlled trial</TI>
<SO>Hemodialysis International</SO>
<YR>2010</YR>
<VL>14</VL>
<NO>2</NO>
<PG>174-81</PG>
<IDENTIFIERS MODIFIED="2013-03-11 10:56:37 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="20041960"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Deira-2003" MODIFIED="2013-03-11 10:59:25 +1100" MODIFIED_BY="[Empty name]" NAME="Deira 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-03-11 10:59:25 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Deira J, Diego J, Martinez R, Oyarbide A, Gonzalez A, Diaz H, et al</AU>
<TI>Comparative study of intravenous ascorbic acid versus low-dose desferroxamine in patients on hemodialysis with hyperferritinemia</TI>
<SO>Journal of Nephrology</SO>
<YR>2003</YR>
<VL>16</VL>
<NO>5</NO>
<PG>703-9</PG>
<IDENTIFIERS MODIFIED="2013-03-11 10:59:25 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-11 10:59:25 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="14733417"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Di-Iorio-2003" MODIFIED="2013-03-11 10:59:43 +1100" MODIFIED_BY="[Empty name]" NAME="Di Iorio 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-03-11 10:59:35 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Di Iorio BR, Bellizzi V, Minutolo R, De Nicola L, Iodice C, Conte G</AU>
<TI>Supplemented very low-protein diet in advanced CRF: is it money saving?</TI>
<SO>Kidney International</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>2</NO>
<PG>742</PG>
<IDENTIFIERS MODIFIED="2013-03-11 10:59:35 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="14717953"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-11 10:59:43 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Di Iorio BR, Minutolo R, De Nicola L, Bellizzi V, Catapano F, Iodice C, et al</AU>
<TI>Supplemented very low protein diet ameliorates responsiveness to erythropoietin in chronic renal failure</TI>
<SO>Kidney International</SO>
<YR>2003</YR>
<VL>64</VL>
<NO>5</NO>
<PG>1822-8</PG>
<IDENTIFIERS MODIFIED="2013-03-11 10:59:43 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="14531817"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ECAP-Study-2006" MODIFIED="2013-04-18 17:56:44 +1000" MODIFIED_BY="[Empty name]" NAME="ECAP Study 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-03-18 13:19:22 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rossert J, Gassmann-Mayer C, Frei D, McClellan W</AU>
<TI>Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>3</NO>
<PG>794-800</PG>
<IDENTIFIERS MODIFIED="2013-03-18 13:19:22 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-18 13:19:22 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17210593"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-04-18 17:45:47 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rossert J, Gassmann-Mayer C, Frei D, McClellan W</AU>
<TI>Prevalence and risk factors for erythropoetin hyporesponsiveness in chronic kidney disease: analysis of the ECAP study [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>Oct</NO>
<PG>141A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-04-18 17:45:55 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rossert J, Levin A, Roger S, Horl W, Gassman-Mayer C, Frei D, et al</AU>
<TI>Effect of early correction of anemia on the progression of chronic kidney disease: final results ECAP study [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>Oct</NO>
<PG>546A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-18 13:23:53 +1100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rossert J, Levin A, Roger SD, Horl WH, Fouqueray B, Gassmann-Mayer C, et al</AU>
<TI>Effect of early correction of anemia on the progression of CKD</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2006</YR>
<VL>47</VL>
<NO>5</NO>
<PG>738-50</PG>
<IDENTIFIERS MODIFIED="2013-03-18 13:21:54 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-18 13:21:54 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16632012"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-04-18 17:46:04 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rossert J, Roger S, Levin A, Horl W, McClellan W</AU>
<TI>Effect on early correction of anemia on the progression of chronic kidney disease (ECAP) [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>Nov</NO>
<PG>811A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eiselt-2000" MODIFIED="2013-03-11 11:02:33 +1100" MODIFIED_BY="[Empty name]" NAME="Eiselt 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-03-11 11:02:33 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eiselt J, Racek J, Opatrny K</AU>
<TI>The effect of hemodialysis and acetate-free biofiltration on anemia</TI>
<SO>International Journal of Artificial Organs</SO>
<YR>2000</YR>
<VL>23</VL>
<NO>3</NO>
<PG>173-80</PG>
<IDENTIFIERS MODIFIED="2013-03-11 11:02:33 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-11 11:02:33 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10795662"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garcia-Cortes-1999" MODIFIED="2013-03-11 11:07:26 +1100" MODIFIED_BY="[Empty name]" NAME="Garcia Cortes 1999" YEAR="2001 Jul">
<REFERENCE MODIFIED="2013-03-11 11:07:05 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garcia Cortes MJ, Sanchez Pearles MC, Perez del Barrio MP, Borrego Utiel FJ, Liebana A, Borrego Hinojosa J, et al</AU>
<TI>Effects of biocompatible membranes on uremic anemia in hemodialysis patients [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>9</NO>
<PG>A260</PG>
<IDENTIFIERS MODIFIED="2013-03-11 11:07:05 +1100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-11 11:07:26 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garcia Cortes MJ, Sanchez Perales MC, Liebana A, Gil JM, Borrego FJ, Borrego J, et al</AU>
<TI>Beneficial effect of AN69 membranes on anemia in hemodialyzed patients</TI>
<SO>Nefrologia</SO>
<YR>2001</YR>
<VL>21</VL>
<NO>4</NO>
<PG>370-5</PG>
<IDENTIFIERS MODIFIED="2013-03-11 11:07:26 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="11816513"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garrote-2009" MODIFIED="2013-08-06 14:40:09 +1000" MODIFIED_BY="[Empty name]" NAME="Garrote 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-08-06 14:40:09 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Garrote N, Guinsburg M, Garcia L, Boubee S, Moretto H, Canale R, et al</AU>
<TI>Vitamin C improves HB levels and reduce EPO resistance in hemodialysis (HD) patients with functional iron deficiency (FID). A randomized, open label, controlled multicentric trial [abstract SA778]</TI>
<SO>World Congress of Nephrology; 2009 May 22-26; Milan (Italy)</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gastaldello-1995" MODIFIED="2013-03-11 11:10:17 +1100" MODIFIED_BY="[Empty name]" NAME="Gastaldello 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-03-11 11:10:17 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gastaldello K, Vereerstraeten A, Nzame-Nze T, Vanherweghem JL, Tielemans C</AU>
<TI>Resistance to erythropoietin in iron-overloaded haemodialysis patients can be overcome by ascorbic acid administration</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>Suppl 6</NO>
<PG>44-7</PG>
<IDENTIFIERS MODIFIED="2013-03-11 11:10:17 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-11 11:10:17 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8524494"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gaughan-1997" MODIFIED="2013-04-18 17:46:40 +1000" MODIFIED_BY="[Empty name]" NAME="Gaughan 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-03-11 11:13:53 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gaughan WJ, Liss KA, Dunn SR, Mangold AM, Buhsmer JP, Michael B, et al</AU>
<TI>A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1997</YR>
<VL>30</VL>
<NO>4</NO>
<PG>495-500</PG>
<IDENTIFIERS MODIFIED="2013-03-11 11:13:53 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-11 11:13:53 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9328363"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-04-18 17:46:40 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liss KA, Gaughan WJ, Dunn SR, Michael B, Goldman JM, Armenti VT, et al</AU>
<TI>A six month study of low-dose recombinant human erythropoietin alone and in combination with androgen for the treatment of anemia in chronic hemodialysis patients [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1996</YR>
<VL>7</VL>
<NO>9</NO>
<PG>1490</PG>
<IDENTIFIERS MODIFIED="2013-03-11 11:15:05 +1100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giancaspro-2000" MODIFIED="2013-03-11 11:17:39 +1100" MODIFIED_BY="[Empty name]" NAME="Giancaspro 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-03-11 11:17:39 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giancaspro V, Nuzziello M, Pallotta G, Sacchetti A, Petrarulo F</AU>
<TI>Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial</TI>
<SO>Journal of Nephrology</SO>
<YR>2000</YR>
<VL>13</VL>
<NO>6</NO>
<PG>444-9</PG>
<IDENTIFIERS MODIFIED="2013-03-11 11:17:39 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-11 11:17:39 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11132761"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hakemi-2005" MODIFIED="2013-04-18 17:46:48 +1000" MODIFIED_BY="[Empty name]" NAME="Hakemi 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-04-18 17:46:48 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hakemi MS, Ganji MR, Najafi I, Shekarchi M</AU>
<TI>Intravenous ascorbic acid in comparison to intravenous iron in erythropoietin resistant anemia with iron overload in hemodialysis patients [abstract]</TI>
<SO>Nephrology</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>Suppl</NO>
<PG>A314</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hsu-2004" MODIFIED="2013-03-11 11:19:26 +1100" MODIFIED_BY="[Empty name]" NAME="Hsu 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-03-11 11:19:26 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hsu PY, Lin CL, Yu CC, Chien CC, Hsiau TG, Sun TH, et al</AU>
<TI>Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients - a prospective cross-over study</TI>
<SO>Journal of Nephrology</SO>
<YR>2004</YR>
<VL>17</VL>
<NO>5</NO>
<PG>693-700</PG>
<IDENTIFIERS MODIFIED="2013-03-11 11:19:26 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-11 11:19:26 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15593037"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hung-2005" MODIFIED="2013-03-11 11:21:28 +1100" MODIFIED_BY="[Empty name]" NAME="Hung 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-03-11 11:21:28 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hung SC, Tung TY, Yang CS, Tarng DC</AU>
<TI>High-calorie supplementation increases serum leptin levels and improves response to rHuEPO in long-term hemodialysis patients</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2005</YR>
<VL>45</VL>
<NO>6</NO>
<PG>1073-83</PG>
<IDENTIFIERS MODIFIED="2013-03-11 11:21:28 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-11 11:21:28 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15957137"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Imada-2001" MODIFIED="2013-04-18 17:47:02 +1000" MODIFIED_BY="[Empty name]" NAME="Imada 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-04-18 17:47:02 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Imada A, Yoshimoto S, Ohno T, Takahashi K, Imada T, Iida N</AU>
<TI>Effect of Vitamin C on recombinant human erythropoietin refractory anemia in patients with chronic hemodialysis [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>Program &amp; Abstracts</NO>
<PG>332A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ISRCTN96315193" MODIFIED="2013-08-01 16:11:12 +1000" MODIFIED_BY="[Empty name]" NAME="ISRCTN96315193" YEAR="2006">
<REFERENCE MODIFIED="2013-08-01 16:11:12 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<TI>Comparison of the effect of erythropoietin, L-carnitine and erythropoietin plus L-carnitine in correction of anemia in chronic hemodialysis patients</TI>
<SO>http://www.controlled-trials.com/ISRCTN96315193/ISRCTN96315193</SO>
<YR>(accessed 11th March 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jacobs-2006" MODIFIED="2013-08-01 16:11:41 +1000" MODIFIED_BY="[Empty name]" NAME="Jacobs 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-08-01 16:11:41 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jacobs C</AU>
<TI>Intravenous vitamin C can improve anemia in erythropoietin-hyporesponsive hemodialysis patients</TI>
<SO>Nature Clinical Practice Nephrology</SO>
<YR>2006</YR>
<VL>2</VL>
<NO>10</NO>
<PG>552-3</PG>
<IDENTIFIERS MODIFIED="2013-08-01 16:11:39 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-08-01 16:11:39 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE=" 17003830"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Janssen-1995" MODIFIED="2013-08-01 16:12:28 +1000" MODIFIED_BY="[Empty name]" NAME="Janssen 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-08-01 16:12:28 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Janssen MJ, van der Kuy A, ter Wee PM, van Boven WP</AU>
<TI>Calcium acetate versus calcium carbonate and erythropoietin dosages in haemodialysis patients</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>12</NO>
<PG>2321-4</PG>
<IDENTIFIERS MODIFIED="2013-08-01 16:12:28 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2013-08-01 16:12:28 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8808233"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kato-2000" MODIFIED="2013-08-01 16:13:05 +1000" MODIFIED_BY="[Empty name]" NAME="Kato 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-08-01 16:13:05 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kato A, Takita T, Furuhashi M, Takahashi T, Maruyama Y, Hishida A</AU>
<TI>No effect of losartan on response to erythropoietin therapy in patients undergoing hemodialysis</TI>
<SO>Nephron</SO>
<YR>2000</YR>
<VL>86</VL>
<NO>4</NO>
<PG>538-9</PG>
<IDENTIFIERS MODIFIED="2013-08-01 16:13:05 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2013-08-01 16:13:05 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11124620"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keven-2003" MODIFIED="2013-04-18 17:47:45 +1000" MODIFIED_BY="[Empty name]" NAME="Keven 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-03-11 13:34:23 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Deicher R, Horl WH</AU>
<TI>Vitamin C for hyporesponsiveness to EPO: a cure for all?</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2003</YR>
<VL>42</VL>
<NO>4</NO>
<PG>848-9</PG>
<IDENTIFIERS MODIFIED="2013-03-11 13:34:15 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="14520639"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-04-18 17:47:45 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keven K, Kutlay S, Nergizoglu G, Duman N, Erturk S</AU>
<TI>The effect of intravenous vitamin C on erythropoietin response in haemodialysis patients [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>Suppl 1</NO>
<PG>229</PG>
<IDENTIFIERS MODIFIED="2013-03-11 13:34:38 +1100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-11 13:34:55 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keven K, Kutlay S, Nergizoglu G, Erturk S</AU>
<TI>Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2003</YR>
<VL>41</VL>
<NO>6</NO>
<PG>1233-9</PG>
<IDENTIFIERS MODIFIED="2013-03-11 13:34:55 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="12776276"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-04-18 17:36:35 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keven K, Kutlay S, Nergizoglu G, Erturk S</AU>
<TI>The effect of Vitamin C on erythropoietin response in hemodialysis patients [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>Program &amp; Abstracts</NO>
<PG>357A-8A</PG>
<IDENTIFIERS MODIFIED="2013-04-18 17:36:35 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klarenbach-2002" MODIFIED="2013-08-01 16:13:56 +1000" MODIFIED_BY="[Empty name]" NAME="Klarenbach 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-08-01 16:13:56 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klarenbach S, Heidenheim AP, Leitch R, Lindsay RM, Daily/Nocturnal Dialysis Study Group</AU>
<TI>Reduced requirement for erythropoietin with quotidian hemodialysis therapy</TI>
<SO>ASAIO Journal</SO>
<YR>2002</YR>
<VL>48</VL>
<NO>1</NO>
<PG>57-61</PG>
<IDENTIFIERS MODIFIED="2013-08-01 16:13:50 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-08-01 16:13:50 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11814098"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kletzmayr-1999" MODIFIED="2013-03-11 13:40:45 +1100" MODIFIED_BY="[Empty name]" NAME="Kletzmayr 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-03-11 13:40:45 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kletzmayr J, Mayer G, Legenstein E, Heinz-Peer G, Leitha T, Horl WH, et al</AU>
<TI>Anemia and carnitine supplementation in hemodialyzed patients</TI>
<SO>Kidney International - Supplement</SO>
<YR>1999</YR>
<VL>55</VL>
<NO>Suppl 69</NO>
<PG>S93-S106</PG>
<IDENTIFIERS MODIFIED="2013-03-11 13:40:45 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-11 13:40:45 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10084293"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koronis-2000" MODIFIED="2013-08-01 16:14:12 +1000" MODIFIED_BY="[Empty name]" NAME="Koronis 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-08-01 16:14:12 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Koronis C, Makris F, Stavroulaki E, Lambropoulou A, Orthopoulos V</AU>
<TI>Combination of low-dose recombinant human erythropoietin with androgens for the treatment of anaemia in hemodialysis patients [abstract]</TI>
<SO>37th Congress. European Renal Association. European Dialysis and Transplantation Association. European Kidney Research Organisation; Nice (France)</SO>
<YR>2000</YR>
<PG>235</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Labonia-1995" MODIFIED="2013-03-11 13:44:54 +1100" MODIFIED_BY="[Empty name]" NAME="Labonia 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-03-11 13:44:54 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Labonia WD</AU>
<TI>L-carnitine effects on anemia in hemodialyzed patients treated with erythropoietin</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1995</YR>
<VL>26</VL>
<NO>5</NO>
<PG>757-64</PG>
<IDENTIFIERS MODIFIED="2013-03-11 13:44:54 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-11 13:44:54 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="7485128"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2001" MODIFIED="2013-04-18 17:57:07 +1000" MODIFIED_BY="[Empty name]" NAME="Lee 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-03-17 10:02:44 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee M, Ahn S, Song J</AU>
<TI>Effects of adjuvant androgen on anemia and nutritional parameters in chronic hemodialysis patients using low-dose recombinant human erythropoietin [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>Program &amp; Abstracts</NO>
<PG>358A-9A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Locatelli-1999" MODIFIED="2013-03-11 13:48:32 +1100" MODIFIED_BY="[Empty name]" NAME="Locatelli 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-03-11 13:48:32 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Locatelli F, Andrulli S, Del Vecchio L</AU>
<TI>Anemia of hemodialysis patients: evaluation of the effect of BK-F polymethylmethacrylate membrane</TI>
<SO>Contributions to Nephrology</SO>
<YR>1999</YR>
<VL>125</VL>
<PG>173-81</PG>
<IDENTIFIERS MODIFIED="2013-03-11 13:48:32 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-11 13:48:32 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9895439"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Locatelli-2000" MODIFIED="2013-03-11 13:50:11 +1100" MODIFIED_BY="[Empty name]" NAME="Locatelli 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-03-11 13:50:11 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Locatelli F, Andrulli S, Pecchini F, Pedrini L, Agliata S, Lucchi L, et al</AU>
<TI>Effect of high-flux dialysis on the anaemia of haemodialysis patients</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>9</NO>
<PG>1399-409</PG>
<IDENTIFIERS MODIFIED="2013-03-11 13:50:11 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-11 13:50:11 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10978398"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malegos-2000" MODIFIED="2013-08-06 14:43:12 +1000" MODIFIED_BY="[Empty name]" NAME="Malegos 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-08-06 14:43:12 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malegos I, Kaloheretis P, Drouzas A, Papadakis I</AU>
<TI>Does haemodialysis membrane's biocompatibility affect recombinant human erythropoietin (rHuEPO) effect on the anemia of hemodialyzed patients? [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>9</NO>
<PG>A156</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miyahara-1990" MODIFIED="2013-08-01 18:09:14 +1000" MODIFIED_BY="[Empty name]" NAME="Miyahara 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-08-01 18:09:14 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miyahara S, Motomori T, Miyazaki F, Noda S, Eto K, Nakamura Y, et al</AU>
<TI>Clinical studies of mepitiostane for treatment of anemia associated with chronic renal failure</TI>
<SO>Kiso to Rinsho (The Clinical Report)</SO>
<YR>1990</YR>
<VL>24</VL>
<NO>5</NO>
<PG>2963-8</PG>
<IDENTIFIERS MODIFIED="2013-03-11 14:05:46 +1100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mydl_x00ed_k-2003" MODIFIED="2013-08-06 14:47:07 +1000" MODIFIED_BY="[Empty name]" NAME="Mydlík 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-08-06 14:47:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mydlík M, Derzsiová K, Boldizsár J, Hríbiková M, Petrovicová J</AU>
<TI>Oral use of iron with vitamin C in hemodialyzed patients</TI>
<SO>Journal of Renal Nutrition</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>1</NO>
<PG>47-51</PG>
<IDENTIFIERS MODIFIED="2013-08-06 14:47:07 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-08-06 14:47:07 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12563623"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nakamoto-2008" MODIFIED="2013-08-06 14:48:12 +1000" MODIFIED_BY="[Empty name]" NAME="Nakamoto 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-08-06 14:48:12 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nakamoto H, Mimura T, Honda N</AU>
<TI>Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis</TI>
<SO>Hemodialysis International</SO>
<YR>2008</YR>
<VL>12</VL>
<NO>Suppl 2</NO>
<PG>S9-S14</PG>
<IDENTIFIERS MODIFIED="2013-03-11 14:18:10 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-11 14:18:10 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18837771"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Navarro-2002" MODIFIED="2013-03-18 10:49:25 +1100" MODIFIED_BY="[Empty name]" NAME="Navarro 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-03-07 17:26:28 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Navarro JF, Mora C, Macia M, Chahin J, Gallego E, Mendez ML, et al</AU>
<TI>Effects of androgen therapy on hematologic and nutritional parameters in elderly peritoneal dialysis patients [abstract]</TI>
<SO>International Urology &amp; Nephrology</SO>
<YR>2001</YR>
<VL>33</VL>
<NO>4</NO>
<PG>715-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-07 17:26:30 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Navarro JF, Mora C, Macia ML, Gallego E, Chahin J, Mendez ML, et al</AU>
<TI>Prospective comparison between rHuEPO and androgens in CAPD patients: impact on hematologic and nutritional parameters [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>Program &amp; Abstracts</NO>
<PG>436A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-18 10:49:25 +1100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Navarro JF, Mora C, Macía M, García J</AU>
<TI>Randomized prospective comparison between erythropoietin and androgens in CAPD patients</TI>
<SO>Kidney International</SO>
<YR>2002</YR>
<VL>61</VL>
<NO>4</NO>
<PG>1537-44</PG>
<IDENTIFIERS MODIFIED="2013-03-18 10:49:25 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-18 10:49:25 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE=" 11918762"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Odabas-2003" MODIFIED="2013-03-18 10:50:15 +1100" MODIFIED_BY="[Empty name]" NAME="Odabas 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-03-18 10:50:15 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Odabas AR, Cetinkaya R, Selcuk Y, Keles S, Bilen H</AU>
<TI>The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis</TI>
<SO>Panminerva medica</SO>
<YR>2003</YR>
<VL>45</VL>
<NO>1</NO>
<PG>59-62</PG>
<IDENTIFIERS MODIFIED="2013-03-18 10:50:15 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-18 10:50:15 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12682621"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ono-1992" MODIFIED="2013-03-18 10:53:12 +1100" MODIFIED_BY="[Empty name]" NAME="Ono 1992" YEAR="1992">
<REFERENCE MODIFIED="2013-03-18 10:53:12 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ono K, Hisasue Y</AU>
<TI>Is folate supplementation necessary in hemodialysis patients on erythropoietin therapy</TI>
<SO>Clinical Nephrology</SO>
<YR>1992</YR>
<VL>38</VL>
<NO>5</NO>
<PG>290-2</PG>
<IDENTIFIERS MODIFIED="2013-03-18 10:53:12 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-18 10:53:12 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="1451343"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Onoyama-1989" MODIFIED="2013-03-18 10:54:15 +1100" MODIFIED_BY="[Empty name]" NAME="Onoyama 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-03-18 10:54:15 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Onoyama K, Sanai T, Motomura K, Fujishima M</AU>
<TI>Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients</TI>
<SO>Journal of Cardiovascular Pharmacology</SO>
<YR>1989</YR>
<VL>13</VL>
<NO>Suppl 3</NO>
<PG>S27-S30</PG>
<IDENTIFIERS MODIFIED="2013-03-18 10:54:15 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-18 10:54:15 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="2474097"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Opatrn_x00ec_-1998" MODIFIED="2013-03-18 13:06:43 +1100" MODIFIED_BY="[Empty name]" NAME="Opatrnì 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-03-18 13:06:43 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Opatrný K Jr, Krouzecký A, Wirth J, Vít L, Eiselt J</AU>
<TI>The effects of a polyacrylonitrile membrane and a membrane made of regenerated cellulose on the plasma concentrations of erythropoietin during hemodialysis</TI>
<SO>Artificial Organs</SO>
<YR>1998</YR>
<VL>22</VL>
<NO>10</NO>
<PG>816-20</PG>
<IDENTIFIERS MODIFIED="2013-03-18 13:06:43 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-18 13:06:43 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9790077"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Panichi-2011" MODIFIED="2013-08-06 14:40:34 +1000" MODIFIED_BY="[Empty name]" NAME="Panichi 2011" YEAR="2009">
<REFERENCE MODIFIED="2013-08-06 14:40:34 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Panichi V, Barattini M, Angelini D, Petrone I, Ferrandello FP, Grazi G, et al</AU>
<TI>A vitamin E-coated polysulfone membrane reduces inflammatory markers and EPO requirement in haemodialysis patients [abstract SA413]</TI>
<SO>World Congress of Nephrology; 2009 May 22-26; Milan (Italy)</SO>
<YR>2009</YR>
<IDENTIFIERS MODIFIED="2013-04-18 17:49:08 +1000" MODIFIED_BY="Narelle S Willis"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-04-18 17:49:17 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Panichi V, Rosati A, Paoletti S, Ferrandello P, Migliori M, Beati S, et al</AU>
<TI>A vitamin E-coated polysulfone membrane reduces serum levels of inflammatory markers and resistance to erythropoietin-stimulating agents in hemodialysis patients: results of a randomized cross-over multicenter trial</TI>
<SO>Blood Purification</SO>
<YR>2011</YR>
<VL>32</VL>
<NO>1</NO>
<PG>7-14</PG>
<IDENTIFIERS MODIFIED="2013-04-18 17:49:17 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER TYPE="MEDLINE" VALUE="21242686"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rao-2003" MODIFIED="2013-03-18 13:13:40 +1100" MODIFIED_BY="[Empty name]" NAME="Rao 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-03-18 13:13:40 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rao M, Muirhead N, Klarenbach S, Moist L, Lindsay RM</AU>
<TI>Management of anemia with quotidian hemodialysis</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2003</YR>
<VL>42</VL>
<NO>1 Suppl</NO>
<PG>18-23</PG>
<IDENTIFIERS MODIFIED="2013-03-18 13:13:40 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-18 13:13:40 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12830439"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Richardson-2003" MODIFIED="2013-04-18 17:49:27 +1000" MODIFIED_BY="[Empty name]" NAME="Richardson 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-04-18 17:49:27 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Richardson D, Lindley E, Bartlett C, Will EJ</AU>
<TI>Biocompatibility and erythropoiesis: - a randomised controlled, single center study of modified cellulose and polysulfone dialysers in a large hemodialysis cohort (n = 177) [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>Program &amp; Abstracts</NO>
<PG>240A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-18 13:15:27 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Richardson D, Lindley EJ, Bartlett C, Will EJ</AU>
<TI>A randomized, controlled study of the consequences of hemodialysis membrane composition on erythropoietic response</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2003</YR>
<VL>42</VL>
<NO>3</NO>
<PG>551-60</PG>
<IDENTIFIERS MODIFIED="2013-03-18 13:15:27 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-18 13:15:27 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12955684"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saxena-1997" MODIFIED="2013-03-18 13:24:37 +1100" MODIFIED_BY="[Empty name]" NAME="Saxena 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-03-18 13:24:37 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saxena S, Dash SC, Tiwari SC, Agarwal SK, Jain PK, Aslam J</AU>
<TI>Effect of nandrolone deconoate on response to low dose erythropoietin (EPO) in anemia of end stage renal disease (ESRD) patients on maintenance hemodialysis (MHD) [abstract]</TI>
<SO>Nephrology</SO>
<YR>1997</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>S310</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sezer-2002" MODIFIED="2013-03-18 13:25:21 +1100" MODIFIED_BY="[Empty name]" NAME="Sezer 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-03-18 13:25:21 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sezer S, Ozdemir FN, Yakupoglu U, Arat Z, Turan M, Haberal M</AU>
<TI>Intravenous ascorbic acid administration for erythropoietin-hyporesponsive anemia in iron loaded hemodialysis patients</TI>
<SO>Artificial Organs</SO>
<YR>2002</YR>
<VL>26</VL>
<NO>4</NO>
<PG>366-70</PG>
<IDENTIFIERS MODIFIED="2013-03-18 13:25:21 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-18 13:25:21 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11952508"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shahrbanoo-2008" MODIFIED="2013-04-18 17:49:42 +1000" MODIFIED_BY="[Empty name]" NAME="Shahrbanoo 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-04-18 17:49:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shahrbanoo K, Taziki O</AU>
<TI>Effect of intravenous ascorbic acid in hemodialysis patients with anemia and hyperferritinemia</TI>
<SO>Saudi Journal of Kidney Diseases &amp; Transplantation</SO>
<YR>2008</YR>
<VL>19</VL>
<NO>6</NO>
<PG>933-6</PG>
<IDENTIFIERS MODIFIED="2013-03-18 13:28:50 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-18 13:28:50 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18974579"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sheashaa-2005" MODIFIED="2013-04-18 17:35:22 +1000" MODIFIED_BY="[Empty name]" NAME="Sheashaa 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-03-18 13:32:35 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sheashaa H, Abdel-Razek W, El Husseini A, Selim A, Hassan N, Abbas T, et al</AU>
<TI>Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis</TI>
<SO>Nephron</SO>
<YR>2005</YR>
<VL>99</VL>
<NO>4</NO>
<PG>c102-6</PG>
<IDENTIFIERS MODIFIED="2013-03-18 13:32:35 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-18 13:32:35 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15703460"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sorge_x002d_Haedicke-2001" MODIFIED="2013-08-06 14:44:52 +1000" MODIFIED_BY="[Empty name]" NAME="Sorge-Haedicke 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-08-06 14:44:52 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sorge-Haedicke B, Goncalves-Marques M, Loew L, Samizadeh A</AU>
<TI>Routine intravenous l-carnitine-supplementation does not reduce erythropoietin (RH-EPO)- requirement in chronic hemodialysis (CHD) patients (P) with renal anemia (RA)</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>6</NO>
<PG>A135</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taji-2004" MODIFIED="2013-03-18 13:42:26 +1100" MODIFIED_BY="[Empty name]" NAME="Taji 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-03-18 13:42:26 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taji Y, Morimoto T, Okada K, Fukuhara S, Fukui T, Kuwahara T</AU>
<TI>Effects of intravenous ascorbic acid on erythropoiesis and quality of life in unselected hemodialysis patients</TI>
<SO>Journal of Nephrology</SO>
<YR>2004</YR>
<VL>17</VL>
<NO>4</NO>
<PG>537-43</PG>
<IDENTIFIERS MODIFIED="2013-03-18 13:42:26 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-18 13:42:26 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15372416"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tarng-1998" MODIFIED="2013-03-18 13:45:57 +1100" MODIFIED_BY="[Empty name]" NAME="Tarng 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-03-18 13:45:57 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tarng DC, Huang TP</AU>
<TI>A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1998</YR>
<VL>13</VL>
<NO>11</NO>
<PG>2867-72</PG>
<IDENTIFIERS MODIFIED="2013-03-18 13:45:57 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-18 13:45:57 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9829492"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tarng-1999" MODIFIED="2013-03-18 13:45:00 +1100" MODIFIED_BY="[Empty name]" NAME="Tarng 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-03-18 13:45:00 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tarng DC, Wei YH, Huang TP, Kuo BI, Yang WC</AU>
<TI>Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia</TI>
<SO>Kidney International</SO>
<YR>1999</YR>
<VL>55</VL>
<NO>6</NO>
<PG>2477-86</PG>
<IDENTIFIERS MODIFIED="2013-03-18 13:45:00 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-18 13:45:00 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10354297"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tarng-2004" MODIFIED="2013-08-01 16:23:26 +1000" MODIFIED_BY="[Empty name]" NAME="Tarng 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-08-01 16:23:26 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tarng DC, Hung SC, Huang TP</AU>
<TI>Effect of intravenous ascorbic acid medication on serum levels of soluble transferrin receptor in hemodialysis patients</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>9</NO>
<PG>2486-93</PG>
<IDENTIFIERS MODIFIED="2013-08-01 16:23:26 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2013-08-01 16:23:26 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="15339999"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ursea-1995" MODIFIED="2013-04-18 17:50:11 +1000" MODIFIED_BY="[Empty name]" NAME="Ursea 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-04-18 17:50:11 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ursea N, Capsa D</AU>
<TI>Faster improvement of the anemia in chronic hemodialysed patients with combined treatment with erythropoetin and essential amino acids ketoanalogues [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>6</NO>
<PG>1051</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Usberti-2002a" MODIFIED="2013-04-18 17:35:37 +1000" MODIFIED_BY="[Empty name]" NAME="Usberti 2002a" YEAR="2002">
<REFERENCE MODIFIED="2013-03-18 13:48:51 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Usberti M, Gerardi G, Bufano G, Tira P, Micheli A, Albertini A, et al</AU>
<TI>Effects of erythropoietin and vitamin E-modified membrane on plasma oxidative stress markers and anemia of hemodialyzed patients</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2002</YR>
<VL>40</VL>
<NO>3</NO>
<PG>590-9</PG>
<IDENTIFIERS MODIFIED="2013-03-18 13:48:51 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-18 13:48:51 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12200812"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Usberti-2002b" MODIFIED="2013-04-18 17:35:33 +1000" MODIFIED_BY="[Empty name]" NAME="Usberti 2002b" YEAR="2002">
<REFERENCE MODIFIED="2013-03-18 13:51:42 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Usberti M, Gerardi G, Micheli A, Tira P, Bufano G, Gaggia P, et al</AU>
<TI>Effects of a vitamin E-bonded membrane and of glutathione on anemia and erythropoietin requirements in hemodialysis patients</TI>
<SO>Journal of Nephrology</SO>
<YR>2002</YR>
<VL>15</VL>
<NO>5</NO>
<PG>558-64</PG>
<IDENTIFIERS MODIFIED="2013-03-18 13:51:42 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-18 13:51:42 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12455724"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vaslaki-2006" MODIFIED="2013-08-01 16:23:50 +1000" MODIFIED_BY="[Empty name]" NAME="Vaslaki 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-08-01 16:23:50 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vaslaki L, Berta K, Ladanyi E, Pethoe F, Karatson A, Misz M, et al</AU>
<TI>Less need for erythropoietin in on-line haemodiafiltration compared to haemodialysis [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>Suppl 5</NO>
<PG>v336</PG>
<IDENTIFIERS MODIFIED="2013-03-18 13:52:02 +1100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-18 13:52:22 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vaslaki L, Major L, Berta K, Karatson A, Misz M, Pethoe F, et al</AU>
<TI>On-line haemodiafiltration versus haemodialysis: stable haematocrit with less erythropoietin and improvement of other relevant blood parameters</TI>
<SO>Blood Purification</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>2</NO>
<PG>163-73</PG>
<IDENTIFIERS MODIFIED="2013-03-18 13:52:22 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="16352871"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2000" MODIFIED="2013-04-18 17:50:29 +1000" MODIFIED_BY="[Empty name]" NAME="Wang 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-04-18 17:50:29 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang M-C, Huang J-J, Liao L-H, Ruaan M-K, Sung J-M, Lan R-R</AU>
<TI>Effect of high-dose folic acid on hemodialysis patients with poor erythropoietin response</TI>
<SO>Dialysis &amp; Transplantation</SO>
<YR>2000</YR>
<VL>29</VL>
<NO>11</NO>
<PG>710-7</PG>
<IDENTIFIERS MODIFIED="2013-03-18 13:56:35 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-18 13:56:35 +1100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="2000401292"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2006" MODIFIED="2013-08-01 16:24:35 +1000" MODIFIED_BY="[Empty name]" NAME="Yang 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-08-01 16:24:35 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang CC, Hsu SP, Wu MS, Hsu SM, Chien CT</AU>
<TI>Effects of vitamin C infusion and vitamin E-coated membrane on hemodialysis-induced oxidative stress</TI>
<SO>Kidney International</SO>
<YR>2006</YR>
<VL>69</VL>
<NO>4</NO>
<PG>706-14</PG>
<IDENTIFIERS MODIFIED="2013-08-01 16:24:35 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2013-08-01 16:24:35 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="16395251"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-04-18 15:41:22 +1000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2013-08-01 16:26:15 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-2008" MODIFIED="2013-08-01 16:25:30 +1000" MODIFIED_BY="[Empty name]" NAME="Johnson 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-08-01 16:25:30 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson DW, Hawley CM, Rosser B, Beller E, Thompson C, Fassett RG, et al</AU>
<TI>Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial</TI>
<SO>BMC Nephrology</SO>
<YR>2008</YR>
<VL>9</VL>
<PG>8</PG>
<IDENTIFIERS MODIFIED="2013-08-01 16:25:30 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2013-08-01 16:25:30 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="18671885"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-03-18 15:35:38 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-18 15:35:38 +1100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ACTRN12608000199314"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01526798" MODIFIED="2013-08-01 16:26:15 +1000" MODIFIED_BY="[Empty name]" NAME="NCT01526798" YEAR="2012">
<REFERENCE MODIFIED="2013-08-01 16:25:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<TI>Improvement of EPO-resistance in hemodialysis patients with chronic inflammation by high cut-off hemodialysis (CIEPO-PILOT)</TI>
<SO>http://www.clinicaltrials.gov/ct2/results?term=NCT01526798</SO>
<YR>(accessed 18th March 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-08-01 16:26:15 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2013-08-01 16:26:15 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CTG" VALUE="NCT01526798"/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-08-06 15:05:24 +1000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-08-01 16:29:14 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Badve-2011" MODIFIED="2013-04-18 17:50:56 +1000" MODIFIED_BY="[Empty name]" NAME="Badve 2011" TYPE="JOURNAL_ARTICLE">
<AU>Badve SV, Hawley CM, Johnson DW</AU>
<TI>Is the problem with the vehicle or the destination? Does high-dose ESA or high haemoglobin contribute to poor outcomes in CKD?</TI>
<SO>Nephrology</SO>
<YR>2011</YR>
<VL>16</VL>
<NO>2</NO>
<PG>144-53</PG>
<IDENTIFIERS MODIFIED="2013-04-18 17:50:56 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2013-04-18 17:50:56 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="21272125"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Benz-1999" MODIFIED="2009-10-28 15:21:15 +1100" MODIFIED_BY="[Empty name]" NAME="Benz 1999" TYPE="JOURNAL_ARTICLE">
<AU>Benz RL, Pressman MR, Hovick ET, Peterson DD</AU>
<TI>A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study)</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1999</YR>
<VL>34</VL>
<NO>6</NO>
<PG>1089-95</PG>
<IDENTIFIERS MODIFIED="2009-10-28 15:21:03 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-10-28 15:21:03 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10585319"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Besarab-1998" MODIFIED="2013-02-07 14:26:36 +1100" MODIFIED_BY="[Empty name]" NAME="Besarab 1998" TYPE="JOURNAL_ARTICLE">
<AU>Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al</AU>
<TI>The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>339</VL>
<NO>9</NO>
<PG>584-90</PG>
<IDENTIFIERS MODIFIED="2013-02-07 14:26:36 +1100" MODIFIED_BY="Ann Jones">
<IDENTIFIER MODIFIED="2013-02-07 14:26:36 +1100" MODIFIED_BY="Ann Jones" TYPE="MEDLINE" VALUE="9718377"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brookhart-2010" MODIFIED="2013-04-18 17:51:09 +1000" MODIFIED_BY="[Empty name]" NAME="Brookhart 2010" TYPE="JOURNAL_ARTICLE">
<AU>Brookhart MA, Schneeweiss S, Avorn J, Bradbury BD, Liu J, Winkelmayer WC</AU>
<TI>Comparative mortality risk of anemia management practices in incident hemodialysis patients</TI>
<SO>JAMA</SO>
<YR>2010</YR>
<VL>303</VL>
<NO>9</NO>
<PG>857-64</PG>
<IDENTIFIERS MODIFIED="2013-04-18 17:51:09 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-04-18 17:51:09 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="20197532"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Eschbach-1989" MODIFIED="2013-03-18 14:01:31 +1100" MODIFIED_BY="[Empty name]" NAME="Eschbach 1989" TYPE="JOURNAL_ARTICLE">
<AU>Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW</AU>
<TI>Treatment of the anemia of progressive renal failure with recombinant human erythropoietin</TI>
<SO>New England Journal of Medicine</SO>
<YR>1989</YR>
<VL>321</VL>
<NO>3</NO>
<PG>158-63</PG>
<IDENTIFIERS MODIFIED="2013-03-18 14:01:31 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-18 14:01:31 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="2747747"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gandra-2010" MODIFIED="2013-04-18 17:51:17 +1000" MODIFIED_BY="[Empty name]" NAME="Gandra 2010" TYPE="JOURNAL_ARTICLE">
<AU>Gandra SR, Finkelstein FO, Bennett AV, Lewis EF, Brazg T, Martin ML</AU>
<TI>Impact of erythropoiesis-stimulating agents on energy and physical function in nondialysis CKD patients with anemia: a systematic review</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2010</YR>
<VL>55</VL>
<NO>3</NO>
<PG>519-34</PG>
<IDENTIFIERS MODIFIED="2013-04-18 17:51:17 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2013-04-18 17:51:17 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="20031287"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2008-08-06 10:45:42 +1000" MODIFIED_BY="Leslee Edwards" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12958120"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-04-18 17:51:47 +1000" MODIFIED_BY="Narelle S Willis" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JP, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kausz-2005" MODIFIED="2009-10-28 15:21:51 +1100" MODIFIED_BY="[Empty name]" NAME="Kausz 2005" TYPE="JOURNAL_ARTICLE">
<AU>Kausz AT, Solid C, Pereira BJ, Collins AJ, St Peter W</AU>
<TI>Intractable anemia among hemodialysis patients: a sign of suboptimal management or a marker of disease?</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2005</YR>
<VL>45</VL>
<NO>1</NO>
<PG>136-47</PG>
<IDENTIFIERS MODIFIED="2009-10-28 15:21:51 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-10-28 15:21:51 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15696453"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-KDOQI-2001" MODIFIED="2013-02-07 14:45:03 +1100" MODIFIED_BY="[Empty name]" NAME="KDOQI 2001" TYPE="JOURNAL_ARTICLE">
<TI>NKF KDOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2001</YR>
<VL>37</VL>
<NO>1 Suppl 1</NO>
<PG>S182-238</PG>
<IDENTIFIERS MODIFIED="2009-10-28 15:25:29 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-10-28 15:25:29 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11229970"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-KDOQI-2006" MODIFIED="2013-08-01 16:28:49 +1000" MODIFIED_BY="[Empty name]" NAME="KDOQI 2006" TYPE="JOURNAL_ARTICLE">
<AU>KDOQI. National Kidney Foundation</AU>
<TI>KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2006</YR>
<VL>47</VL>
<NO>5 Suppl 3</NO>
<PG>S11-145</PG>
<IDENTIFIERS MODIFIED="2013-08-01 16:28:48 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2013-08-01 16:28:48 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="16678659"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kilpatrick-2008" MODIFIED="2013-04-18 17:52:27 +1000" MODIFIED_BY="[Empty name]" NAME="Kilpatrick 2008" TYPE="JOURNAL_ARTICLE">
<AU>Kilpatrick RD, Critchlow CW, Fishbane S, Besarab A, Stehman-Breen C, Krishnan M, et al</AU>
<TI>Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients</TI>
<SO>Clinical Journal of The American Society of Nephrology: CJASN</SO>
<YR>2008</YR>
<VL>3</VL>
<NO>4</NO>
<PG>1077-83</PG>
<IDENTIFIERS MODIFIED="2013-02-07 14:41:00 +1100" MODIFIED_BY="Ann Jones">
<IDENTIFIER MODIFIED="2013-02-07 14:41:00 +1100" MODIFIED_BY="Ann Jones" TYPE="MEDLINE" VALUE="18417744"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Locatelli-2004" MODIFIED="2013-08-01 16:29:14 +1000" MODIFIED_BY="[Empty name]" NAME="Locatelli 2004" TYPE="JOURNAL_ARTICLE">
<AU>Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, et al</AU>
<TI>Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>Suppl 2</NO>
<PG>ii1-47</PG>
<IDENTIFIERS MODIFIED="2009-10-28 15:23:59 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-10-28 15:23:59 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15206425"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Macdougall-2002" MODIFIED="2013-02-07 14:43:05 +1100" MODIFIED_BY="Leslee Edwards" NAME="Macdougall 2002" TYPE="JOURNAL_ARTICLE">
<AU>Macdougall IC, Cooper AC</AU>
<TI>Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>Suppl 11</NO>
<PG>39-43</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12386257"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Messana-2009" MODIFIED="2013-02-07 14:44:12 +1100" MODIFIED_BY="[Empty name]" NAME="Messana 2009" TYPE="JOURNAL_ARTICLE">
<AU>Messana JM, Chuang CC, Turenne M, Wheeler J, Turner J, Sleeman K, et al</AU>
<TI>Association of quarterly average achieved hematocrit with mortality in dialysis patients: a time-dependent comorbidity-adjusted model</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2009</YR>
<VL>53</VL>
<NO>3</NO>
<PG>503-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="19185402"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Palmer-2010" MODIFIED="2013-02-07 14:47:49 +1100" MODIFIED_BY="[Empty name]" NAME="Palmer 2010" TYPE="JOURNAL_ARTICLE">
<AU>Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, et al</AU>
<TI>Meta-analysis: Erythropoiesis-stimulating agents in patients with chronic kidney disease</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2010</YR>
<VL>153</VL>
<NO>1</NO>
<PG>23-33</PG>
<IDENTIFIERS MODIFIED="2013-02-07 14:47:39 +1100" MODIFIED_BY="Ann Jones">
<IDENTIFIER MODIFIED="2013-02-07 14:47:39 +1100" MODIFIED_BY="Ann Jones" TYPE="MEDLINE" VALUE="20439566"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pfeffer-2009" MODIFIED="2013-04-18 17:58:01 +1000" MODIFIED_BY="[Empty name]" NAME="Pfeffer 2009" TYPE="JOURNAL_ARTICLE">
<AU>Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al</AU>
<TI>A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>361</VL>
<NO>21</NO>
<PG>2019-32</PG>
<IDENTIFIERS MODIFIED="2013-02-07 14:49:35 +1100" MODIFIED_BY="Ann Jones">
<IDENTIFIER MODIFIED="2013-02-07 14:49:35 +1100" MODIFIED_BY="Ann Jones" TYPE="MEDLINE" VALUE="19880844"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Phrommintikul-2007" MODIFIED="2013-04-18 17:52:50 +1000" MODIFIED_BY="[Empty name]" NAME="Phrommintikul 2007" TYPE="JOURNAL_ARTICLE">
<AU>Phrommintikul A, Haas SJ, Elsik M, Krum H</AU>
<TI>Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis</TI>
<SO>Lancet</SO>
<YR>2007</YR>
<VL>369</VL>
<NO>9559</NO>
<PG>381-8</PG>
<IDENTIFIERS MODIFIED="2013-04-18 17:52:50 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2013-04-18 17:52:50 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="17276778"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Regidor-2006" MODIFIED="2013-04-18 17:52:59 +1000" MODIFIED_BY="[Empty name]" NAME="Regidor 2006" TYPE="JOURNAL_ARTICLE">
<AU>Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, et al</AU>
<TI>Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>4</NO>
<PG>1181-91</PG>
<IDENTIFIERS MODIFIED="2013-04-18 17:52:59 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2013-04-18 17:52:59 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="16565261"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Singh-2006" MODIFIED="2013-04-18 17:53:56 +1000" MODIFIED_BY="[Empty name]" NAME="Singh 2006" TYPE="JOURNAL_ARTICLE">
<AU>Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al</AU>
<TI>Correction of anemia with epoetin alfa in chronic kidney disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>355</VL>
<NO>20</NO>
<PG>2085-98</PG>
<IDENTIFIERS MODIFIED="2013-04-18 17:53:56 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2013-04-18 17:53:56 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="17108343"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Solomon-2010" MODIFIED="2013-04-18 17:58:06 +1000" MODIFIED_BY="[Empty name]" NAME="Solomon 2010" TYPE="JOURNAL_ARTICLE">
<AU>Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, et al</AU>
<TI>Erythropoietic response and outcomes in kidney disease and type 2 diabetes</TI>
<SO>New England Journal of Medicine</SO>
<YR>2010</YR>
<VL>363</VL>
<NO>12</NO>
<PG>1146-55</PG>
<IDENTIFIERS MODIFIED="2013-02-07 15:17:00 +1100" MODIFIED_BY="Ann Jones">
<IDENTIFIER MODIFIED="2013-02-07 15:17:00 +1100" MODIFIED_BY="Ann Jones" TYPE="MEDLINE" VALUE="20843249"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Szczech-2008" MODIFIED="2013-02-07 15:17:33 +1100" MODIFIED_BY="[Empty name]" NAME="Szczech 2008" TYPE="JOURNAL_ARTICLE">
<AU>Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, et al</AU>
<TI>Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes</TI>
<SO>Kidney International</SO>
<YR>2008</YR>
<VL>74</VL>
<NO>6</NO>
<PG>791-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="18596733"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Valderrabano-1996" MODIFIED="2013-02-07 15:17:19 +1100" MODIFIED_BY="[Empty name]" NAME="Valderrabano 1996" TYPE="JOURNAL_ARTICLE">
<AU>Valderrabano F</AU>
<TI>Erythropoietin in chronic renal failure</TI>
<SO>Kidney International</SO>
<YR>1996</YR>
<VL>50</VL>
<NO>4</NO>
<PG>1373-91</PG>
<IDENTIFIERS MODIFIED="2009-10-28 15:25:38 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-10-28 15:25:38 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8887302"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zhang-2004" MODIFIED="2009-10-28 15:26:03 +1100" MODIFIED_BY="[Empty name]" NAME="Zhang 2004" TYPE="JOURNAL_ARTICLE">
<AU>Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ</AU>
<TI>Epoetin requirements predict mortality in hemodialysis patients</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2004</YR>
<VL>44</VL>
<NO>5</NO>
<PG>866-76</PG>
<IDENTIFIERS MODIFIED="2009-10-28 15:26:03 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-10-28 15:26:03 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15492953"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zhang-2009" MODIFIED="2013-04-18 17:53:41 +1000" MODIFIED_BY="[Empty name]" NAME="Zhang 2009" TYPE="JOURNAL_ARTICLE">
<AU>Zhang Y, Thamer M, Cotter D, Kaufman J, Hernan MA</AU>
<TI>Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States</TI>
<SO>Clinical Journal of The American Society of Nephrology: CJASN</SO>
<YR>2009</YR>
<VL>4</VL>
<NO>3</NO>
<PG>638-44</PG>
<IDENTIFIERS MODIFIED="2013-04-18 17:53:41 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-04-18 17:53:41 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="19261818"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-08-06 15:05:24 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Badve-2010" MODIFIED="2013-08-06 15:05:24 +1000" MODIFIED_BY="[Empty name]" NAME="Badve 2010" TYPE="COCHRANE_PROTOCOL">
<AU>Badve SV, Beller E, Cass A, Francis DP, Hawley C, Macdougall IC, et al</AU>
<TI>Interventions for erythropoietin-resistant anaemia in dialysis patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2013-08-06 15:05:08 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-08-06 15:05:08 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006861.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2013-03-18 14:47:25 +1100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-08-07 08:48:17 +1000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-08-07 08:48:08 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-08-06 15:30:39 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Attallah-2006">
<CHAR_METHODS MODIFIED="2013-08-01 17:01:44 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 6 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-06 15:30:39 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: USA</LI>
<LI>Setting: large inner-city HD centre</LI>
<LI>Inclusion criteria: ESKD patients receiving HD therapy for at least 6 months; administered IV EPO &#8805; 6 months at dose &#8805; 450 U/kg/wk; 3 month average Hb level &#8804; 11 g/dL; ferritin level &gt; 500 ng/mL; TSAT &#8804; 50% and administered maintenance IV iron</LI>
<LI>Number (treatment/control): 20/22</LI>
<LI>Age (mean ± SD) years: treatment group (50.6 ± 4.7); control group (49.0 ± 5.9)</LI>
<LI>Sex (M/F): treatment group (9/11); control group (10/12)</LI>
<LI>Exclusion criteria: bone marrow malignancy; myelodysplastic syndrome; chronic infection; haemochromatosis; haemoglobinopathies; significant bleeding (decrease in Hb &gt; 2 g/L) during the past 3 months; mean corpuscular volume &gt; 100 fL; CRP &gt; 20 mg/dL; Bio-PTH &gt; 500 pg/mL (ng/L); aluminium level &gt; 20 µg/L</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-01 16:53:27 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Vitamin C</LI>
<UL>
<LI>Dose: 300 mg IV on each dialysis session</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>No treatment</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-07 12:39:58 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Hb level</LI>
<LI>EPO dose</LI>
<LI>Iron studies</LI>
<LI>CRP</LI>
<LI>Blood transfusion</LI>
<LI>Hospitalisation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-01 16:33:50 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Patients were to be withdrawn from the study if they developed bone marrow malignancy, myelodysplastic syndrome, haemochromatosis, or blood loss of &#8805; 500 mL during the 6 month study period</LI>
<LI>Patients on peritoneal dialysis were excluded from the study.</LI>
<LI>One patient from the control arm was excluded because of significant upper gastrointestinal bleeding</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-07 08:48:08 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ayli-2004">
<CHAR_METHODS MODIFIED="2013-08-01 17:01:36 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: RCT</LI>
<LI>Time frame: NS</LI>
<LI>Follow-up period: 6 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-07 08:47:55 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Turkey</LI>
<LI>Setting: single centre</LI>
<LI>Inclusion criteria: ESKD patients receiving HD; administered SC EPO &#8805; 6 months at &#8805; 200 U/kg/wk; Hb level &#8804; 11 g/dL</LI>
<LI>Number (treatment/control): 24/24</LI>
<LI>Age (mean ± SD) years: treatment group (59.9 ± 14.9); control group (58.3 ± 13.1)</LI>
<LI>Sex (M/F): treatment group (12/12); control group (14/10)</LI>
<LI>Exclusion criteria: iron deficiency; chronic blood loss; acute or chronic infection; malnutrition; haemolysis; vitamin B<SUB>12</SUB> or folic acid deficiency; haemoglobinopathies; malignancy; treatment with ACEi or ARB</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-01 16:57:27 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Polysulphone high-flux dialyser (Fresenius F60)</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Polysulphone low-flux dialyser (Fresenius F6 HPS)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-07 08:48:08 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Hb level</LI>
<LI>HCT level</LI>
<LI>EPO dose</LI>
<LI>Iron studies</LI>
<LI>CRP</LI>
<LI>Vitamin B<SUB>12</SUB> and folic acid levels</LI>
<LI>Dialysis adequacy tests (urea reduction ratio and Kt/V urea)</LI>
<LI>Beta 2 microglobulin</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-01 16:57:35 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Patients on peritoneal dialysis were excluded from the study</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ACEi - angiotensin-converting enzyme inhibitor; ARB - angiotensin-II receptor blocker; CRP - C-reactive protein; DPO - darbepoetin; EPO - erythropoietin; ESKD - end-stage kidney disease; GFR - glomerular filtration rate; Hb - haemoglobin; HCT - haematocrit; HD - haemodialysis; IV - intravenous; NS - not stated; PTH - parathyroid hormone; RCT - randomised controlled trial; SC - subcutaneous; TSAT - transferin saturation</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-08-06 14:30:09 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:13:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abe-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:13:21 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:13:35 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Acchiardo-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:13:35 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:13:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aliev-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:13:44 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:13:49 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Andrulli-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:13:49 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:13:53 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ballal-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:13:53 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:13:59 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barany-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:13:59 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:14:04 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Berns-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:14:04 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:14:09 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brockenbrough-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:14:09 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:17:12 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Buchwald-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:17:12 +1000" MODIFIED_BY="[Empty name]">
<P>ESA was not used.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:14:18 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cao-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:14:18 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:14:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Caruso-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:14:23 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 17:55:10 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cerulli-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:35:56 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:15:37 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chan-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:15:37 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:15:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:15:41 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-06 16:55:17 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cruz-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-06 16:55:17 +1100" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:18:02 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Culleton-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:18:02 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:18:06 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Deira-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:18:06 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:18:24 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Di-Iorio-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:18:24 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-17 12:26:18 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ECAP-Study-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-17 12:26:18 +1100" MODIFIED_BY="[Empty name]">
<P>Ineligible patient population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 16:17:35 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eiselt-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 16:17:35 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:37:33 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garcia-Cortes-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:37:33 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-06 11:32:16 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garrote-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-06 11:32:16 +1000" MODIFIED_BY="[Empty name]">
<P>Ineligible patient population (this study included iron deficient patients who lacked true ESA resistance).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-06 16:56:01 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gastaldello-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-06 16:56:01 +1100" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:18:31 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gaughan-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:18:31 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-06 11:32:32 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Giancaspro-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-06 11:32:32 +1000" MODIFIED_BY="[Empty name]">
<P>Ineligible patient population (this study included iron deficient patients who lacked true ESA resistance).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:19:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hakemi-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:19:41 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:19:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hsu-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:19:44 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:19:51 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hung-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:19:51 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:19:55 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Imada-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:19:55 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:19:59 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ISRCTN96315193">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:19:59 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 17:54:56 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jacobs-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:20:14 +1000" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:20:43 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Janssen-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:20:43 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:20:48 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kato-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:20:48 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:20:52 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Keven-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:20:52 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-06 16:57:00 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Klarenbach-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-06 16:57:00 +1100" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:20:59 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kletzmayr-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:20:59 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:21:03 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koronis-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:21:03 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:21:06 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Labonia-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:21:06 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:21:14 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lee-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:21:14 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 17:55:30 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Locatelli-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:21:37 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:21:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Locatelli-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:21:21 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:21:43 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Malegos-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:21:43 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:21:47 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Miyahara-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:21:47 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-06 16:57:30 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mydl_x00ed_k-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-06 16:57:30 +1100" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 17:55:35 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nakamoto-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:25:32 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-06 11:48:31 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Navarro-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-06 11:48:31 +1000" MODIFIED_BY="[Empty name]">
<P>ESA not used in the control arm (compared erythropoietin to androgens)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:25:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Odabas-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:25:41 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:25:46 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ono-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:25:46 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:25:50 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Onoyama-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:25:50 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:25:55 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Opatrn_x00ec_-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:25:55 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:26:12 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Panichi-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:26:12 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-06 16:58:09 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rao-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-06 16:58:09 +1100" MODIFIED_BY="[Empty name]">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:26:18 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Richardson-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:26:18 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:26:22 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saxena-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:26:22 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:26:25 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sezer-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:26:25 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:26:28 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shahrbanoo-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:26:28 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:26:35 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sheashaa-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:26:35 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:26:39 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sorge_x002d_Haedicke-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:26:39 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:26:43 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Taji-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:26:43 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:26:46 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tarng-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:26:46 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:26:52 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tarng-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:26:52 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:26:57 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tarng-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:26:57 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:27:00 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ursea-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:27:00 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:27:02 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Usberti-2002a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:27:02 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:27:07 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Usberti-2002b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:27:07 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:27:11 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vaslaki-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:27:11 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:27:15 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:27:15 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-18 15:27:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yang-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-18 15:27:17 +1000" MODIFIED_BY="[Empty name]">
<P>Study participants did not have ESA resistance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>ESA - Erythropoiesis-simulating agents; RCT - randomised control trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2013-04-18 15:41:22 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2013-08-07 08:48:17 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2013-08-07 08:48:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnson-2008">
<CHAR_STUDY_NAME MODIFIED="2013-08-06 15:06:49 +1000" MODIFIED_BY="[Empty name]">
<P>The Hemoglobin elevation in Erythropoietin Resistance with Oxpentifylline (<A HREF="http://www.anzctr.org.au/trial_view.aspx?id=82696">HERO Study</A>)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-02-06 15:16:53 +1100" MODIFIED_BY="[Empty name]">
<P>Investigator-initiated, prospective, double-blind, randomised, placebo-controlled phase 3 trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-07 08:48:17 +1000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria</P>
<UL>
<LI>Adults aged &#8805;18 years with CKD stage 4 or 5 (on dialysis or eGFR &lt; 30 mL/min/1.73 m²) able to give informed consent and who have Hb concentration &lt; 110 g/L for at least 3 months in spite of EPO dose &#8805; 200 IU/kg/wk or DPO dose &#8805; 1 &#956;g/kg/wk for at least 1 month. Revised criteria based on ESA-resistance index &#8805; 1.0 IU/kg/wk/g Hb for epoetin-treated patients and &#8805; 0.005 µg/kg/wk/g Hb for DPO-treated patients.</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Patients with a history of psychological illness or condition which interferes with their ability to understand or comply with the requirements of the study</LI>
<LI>Pregnancy or breastfeeding</LI>
<LI>Known hypersensitivity to, or intolerance of, oxpentifylline or other methylxanthines, such as caffeine, theophylline or theobromine</LI>
<LI>Active peptic ulcer disease</LI>
<LI>Absolute or functional iron deficiency (ferritin &lt; 100 µg/L and/or TSAT &lt; 20%)</LI>
<LI>Vitamin B<SUB>12</SUB> or folate deficiency</LI>
<LI>PTH &gt; 100 pmol/L</LI>
<LI>Serum aluminium &gt; 2 &#956;mol/L</LI>
<LI>Urea reduction ratio &lt; 65% or single pool Kt/V &lt; 1.0 (HD patients) or total weekly Kt/V &lt; 1.7 (PD patients)</LI>
<LI>Presence of systemic haematological disease (including antibody-mediated pure red cell aplasia) or known haemoglobinopathy</LI>
<LI>Major surgery, infection, acute myocardial infarction or malignancy within the last 3 months</LI>
<LI>Melatonin treatment, androgen therapy or blood transfusion within the previous month</LI>
<LI>Vitamin C therapy &gt; 100 mg/d or at a dose that has changed within the last 3 months</LI>
<LI>Haemorrhagic stroke or severe haemorrhage within the last 3 months.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-01 17:05:24 +1000" MODIFIED_BY="[Empty name]">
<P>Intervention arm</P>
<UL>
<LI>Oxpentifylline 400 mg once daily</LI>
</UL>
<P>Control arm</P>
<UL>
<LI>Identical placebo 1 tablet once daily</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-06 15:29:04 +1000" MODIFIED_BY="[Empty name]">
<P>Primary: difference in Hb concentration between the oxpentifylline and control groups at the end of the 4 month study period</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-04-18 15:40:51 +1000" MODIFIED_BY="[Empty name]">
<P>April 2008</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-04-18 15:39:51 +1000" MODIFIED_BY="[Empty name]">
<P>Professor David Johnson, Level 2 ARTS Building, Princess Alexandra Hospital, Woolloongabba 4102 Queensland, Australia Tel: 61-7-31765080, Fax: 61-7-31765480, Email: David_Johnson@health.qld.gov.au </P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-08-06 15:29:22 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01526798">
<CHAR_STUDY_NAME MODIFIED="2013-04-18 15:46:57 +1000" MODIFIED_BY="[Empty name]">
<P>Improvement of EPO-resistance in Hemodialysis Patients With Chronic Inflammation by High Cut-off Hemodialysis (CIEPO-PILOT)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-08-01 17:05:44 +1000" MODIFIED_BY="[Empty name]">
<P>Open-label RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-06 15:29:22 +1000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria</P>
<UL>
<LI>ESKD treated with chronic HD for at least 3 months</LI>
<LI>Treatment with high-flux dialyzers for at least 3 months</LI>
<LI>Age &#8805;18 years</LI>
<LI>Receiving ESA to treat anaemia for at least 3 months</LI>
<LI>Impaired ESA responsiveness as indicated by EPO resistance index &gt; median of patients in study centre</LI>
<LI>TSAT &#8805; 20% (last routine value prior to randomisation)</LI>
<LI>Serum ferritin &#8805; 100 ng/mL (last routine value prior to randomisation)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Acute infection &#8804; 4 weeks prior to randomisation</LI>
<LI>HIV or hepatitis infection</LI>
<LI>Catheter</LI>
<LI>Chronic liver disease</LI>
<LI>Active cancer</LI>
<LI>Known blood dyscrasia (paraprotein abnormalities)</LI>
<LI>Known bleeding disorders</LI>
<LI>Bleeding episode &#8804; 12 weeks prior to randomisation</LI>
<LI>Blood/red cell transfusion &#8804; 12 weeks prior to randomisation</LI>
<LI>Hypoalbuminaemia defined as serum albumin concentration below 35 g/L (last routine value prior to randomisation)</LI>
<LI>Participation in another clinical interventional investigation</LI>
<LI>Pregnancy</LI>
<LI>Inability to give informed consent</LI>
<LI>Planned transplantation within study period + 3 months</LI>
<LI>Planned interventions requiring hospitalisation &gt;1 week</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-06 14:32:49 +1000" MODIFIED_BY="[Empty name]">
<P>Intervention arm: Device: Theralite (high cut-off HD), HD with Theralite dialyzer alternating with standard high-flux dialyzer (Polyflux H)</P>
<P>Control arm: Device: Polyflux H, Conventional high-flux dialyzer</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-06 14:31:52 +1000" MODIFIED_BY="[Empty name]">
<P>EPO resistance index</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-04-18 15:53:55 +1000" MODIFIED_BY="[Empty name]">
<P>March 2012</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-04-18 15:55:35 +1000" MODIFIED_BY="[Empty name]">
<P>Dr. Ugo Teatini, Azienda Ospedaliera Garbagnate Milanese Ospedale Bollate - Divisione Nefrologia e Dialisi, Bollate, Milan, Italy, 20021</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-04-18 15:54:49 +1000" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<FOOTNOTES>
<P>CKD - chronic kidney disease; DPO - darbepoetin; EPO - erythropoietin; eGFR - estimated glomerular filtration rate; ESA - erythropoiesis-stimulating agent; Hb - haemoglobin; HD - haemodialysis; PD - peritoneal dialysis; PTH - parathyroid hormone; RCT - randomised controlled trial; TSAT - transferrin saturation</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-02-07 12:40:24 +1100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-07-18 11:15:56 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-18 11:15:56 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Attallah-2006">
<DESCRIPTION>
<P>Randomisation was performed with blocks of 4</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-01 11:19:04 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ayli-2004">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-02-06 16:50:55 +1100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 16:50:55 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Attallah-2006">
<DESCRIPTION>
<P>Stated "concealed randomisation was performed using 1:1 allocation ratio with blocks of 4". No further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-01 11:19:11 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ayli-2004">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-09-01 11:19:21 +1000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Investigators</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.03" NO="3">
<NAME>Outcome assessors</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>Participants</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-09-01 11:18:28 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Attallah-2006">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-09-01 11:18:41 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Attallah-2006">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2011-09-01 11:18:47 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Attallah-2006">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-09-01 11:19:14 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ayli-2004">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-09-01 11:19:17 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ayli-2004">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2011-09-01 11:19:21 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ayli-2004">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2012-07-18 11:16:24 +1000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-18 11:15:50 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Attallah-2006">
<DESCRIPTION>
<P>All patients were followed up or accounted for at 6 months</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-18 11:16:24 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ayli-2004">
<DESCRIPTION>
<P>All patients were followed up or accounted for at 6 months</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-02-07 12:40:24 +1100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-07 12:40:24 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Attallah-2006">
<DESCRIPTION>
<P>Hb changes in individual patient data are presented in figures only. It was unclear how many patients in each arm achieved target Hb</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-06 16:54:46 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ayli-2004">
<DESCRIPTION>
<P>Proportion of participants in each arm achieving target haemoglobin is not described. Data on mean EPO dose presented in figure only</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2012-07-18 11:16:26 +1000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-18 11:15:44 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Attallah-2006">
<DESCRIPTION>
<P>Single-centre study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-18 11:16:26 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ayli-2004">
<DESCRIPTION>
<P>Single-centre study, patients on peritoneal dialysis were excluded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2013-08-06 15:40:21 +1000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2013-08-06 15:40:21 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-02-06 18:27:33 +1100" MODIFIED_BY="[Empty name]">Current definitions of ESA resistance</TITLE>
<TABLE COLS="2" ROWS="8">
<TR>
<TH>
<P>Author/study</P>
</TH>
<TH>
<P>Definition of ESA resistance</P>
</TH>
</TR>
<TR>
<TD>
<P>KDOQI (<LINK REF="REF-KDOQI-2006" TYPE="REFERENCE">KDOQI 2006</LINK>)</P>
</TD>
<TD>
<P>Epoetin dose &gt; 500 IU/kg/wk</P>
</TD>
</TR>
<TR>
<TD>
<P>Normal Haematocrit Cardiac Trial (<LINK REF="REF-Besarab-1998" TYPE="REFERENCE">Besarab 1998</LINK>)</P>
</TD>
<TD>
<P>Epoetin dose 440 IU/kg/wk in the normal haematocrit group</P>
</TD>
</TR>
<TR>
<TD>
<P>CHOIR study (<LINK REF="REF-Szczech-2008" TYPE="REFERENCE">Szczech 2008</LINK>)</P>
</TD>
<TD>
<P>Epoetin dose &gt; 20,000 IU/wk</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Attallah-2006" TYPE="STUDY">Attallah 2006</LINK>
</P>
</TD>
<TD>
<P>Epoetin dose &gt; 450 IU/kg/wk (IV)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ayli-2004" TYPE="STUDY">Ayli 2004</LINK>
</P>
</TD>
<TD>
<P>Epoetin dose &gt; 200 IU/kg/wk (SC)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Johnson-2008" TYPE="STUDY">Johnson 2008</LINK>; <A HREF="http://www.anzctr.org.au/trial_view.aspx?id=82696">HERO Study</A>
</P>
</TD>
<TD>
<P>Epoetin dose &#8805; 200 IU/kg/wk or darbepoetin dose &#8805; 1 &#956;g/kg/wk</P>
</TD>
</TR>
<TR>
<TD>
<P>
<A HREF="http://www.anzctr.org.au/trial_view.aspx?id=82696">HERO Study</A> (revised criteria)</P>
</TD>
<TD>
<P>ESA-resistance index (ERI) &#8805; 1.0 IU/kg/wk/g Hb for epoetin-treated patients and &#8805; 0.005 µg/kg/wk/g Hb for darbepoetin-treated patients</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Hb - haemoglobin</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-08-07 08:46:59 +1000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-04-18 17:19:38 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Clinical outcomes</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-04-18 17:19:11 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="20" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Non-fatal cardiovascular events</NAME>
<GROUP_LABEL_1>Vitamin C</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vitamin C</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.086598927966873" CI_START="0.20091896111960805" EFFECT_SIZE="0.7875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.48948020101205375" LOG_CI_START="-0.6969790760887775" LOG_EFFECT_SIZE="-0.1037494375383619" MODIFIED="2011-03-17 15:32:39 +1100" MODIFIED_BY="[Empty name]" ORDER="7" O_E="0.0" SE="0.6969320524371695" STUDY_ID="STD-Attallah-2006" TOTAL_1="20" TOTAL_2="21" VAR="0.4857142857142856" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-04-18 17:19:38 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="20" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Hospitalisations</NAME>
<GROUP_LABEL_1>Vitamin C</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Vitamin C</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.655850879808419" CI_START="0.55947444380208" EFFECT_SIZE="0.9625" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.21902122315394557" LOG_CI_START="-0.25221974679286896" LOG_EFFECT_SIZE="-0.016599261819461704" MODIFIED="2010-04-23 09:54:53 +1000" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.27680927842718106" STUDY_ID="STD-Attallah-2006" TOTAL_1="20" TOTAL_2="21" VAR="0.07662337662337664" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-08-07 08:46:59 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Haematology and biochemistry results</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2013-08-01 18:14:20 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="44" TOTAL_2="45" UNITS="g/dL" WEIGHT="0.0" Z="0.0">
<NAME>Haemoglobin</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.01" MODIFIED="2013-08-01 18:13:01 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Vitamin C versus control</NAME>
<CONT_DATA CI_END="1.4221610029138798" CI_START="0.377838997086121" EFFECT_SIZE="0.9000000000000004" ESTIMABLE="YES" MEAN_1="10.5" MEAN_2="9.6" MODIFIED="2010-04-23 10:18:30 +1000" MODIFIED_BY="[Empty name]" ORDER="4" SD_1="0.9" SD_2="0.8" SE="0.26641357036793467" STUDY_ID="STD-Attallah-2006" TOTAL_1="20" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.02" MODIFIED="2013-08-01 18:13:06 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>High-flux versus low-flux dialyser</NAME>
<CONT_DATA CI_END="2.1561736159720426" CI_START="1.643826384027958" EFFECT_SIZE="1.9000000000000004" ESTIMABLE="YES" MEAN_1="11.4" MEAN_2="9.5" MODIFIED="2013-08-01 18:13:06 +1000" MODIFIED_BY="Narelle S Willis" ORDER="10" SD_1="0.5" SD_2="0.4" SE="0.13070322617798436" STUDY_ID="STD-Ayli-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2013-08-01 18:20:38 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="24" TOTAL_2="24" UNITS="%" WEIGHT="0.0" Z="0.0">
<NAME>Haematocrit</NAME>
<GROUP_LABEL_1>High-flux dialyser</GROUP_LABEL_1>
<GROUP_LABEL_2>Low-flux dialyser</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low-flux</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours high-flux</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.93299933329575" CI_START="5.6670006667042445" EFFECT_SIZE="6.799999999999997" ESTIMABLE="YES" MEAN_1="35.8" MEAN_2="29.0" MODIFIED="2011-09-01 11:51:38 +1000" MODIFIED_BY="[Empty name]" ORDER="11" SD_1="2.1" SD_2="1.9" SE="0.5780715065341542" STUDY_ID="STD-Ayli-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2013-08-01 18:20:38 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="44" TOTAL_2="45" UNITS="%" WEIGHT="0.0" Z="0.0">
<NAME>Transferin saturation (TSAT)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.03.01" MODIFIED="2013-08-01 18:16:21 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Vitamin C versus control</NAME>
<CONT_DATA CI_END="9.778426578665766" CI_START="6.221573421334228" EFFECT_SIZE="7.9999999999999964" ESTIMABLE="YES" MEAN_1="37.3" MEAN_2="29.3" MODIFIED="2011-03-17 15:55:30 +1100" MODIFIED_BY="[Empty name]" ORDER="10" SD_1="3.0" SD_2="2.8" SE="0.9073771725877466" STUDY_ID="STD-Attallah-2006" TOTAL_1="20" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.03.02" MODIFIED="2013-08-01 18:16:54 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>High-flux versus low-flux dialyser</NAME>
<CONT_DATA CI_END="6.592053987886188" CI_START="-3.9920539878861936" EFFECT_SIZE="1.2999999999999972" ESTIMABLE="YES" MEAN_1="35.8" MEAN_2="34.5" MODIFIED="2013-08-01 18:16:54 +1000" MODIFIED_BY="Narelle S Willis" ORDER="12" SD_1="9.6" SD_2="9.1" SE="2.7000771593913138" STUDY_ID="STD-Ayli-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2013-08-01 18:20:38 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="44" TOTAL_2="45" UNITS="ng/mL" WEIGHT="0.0" Z="0.0">
<NAME>Ferritin</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.04.01" MODIFIED="2013-08-01 18:18:04 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Vitamin C versus control</NAME>
<CONT_DATA CI_END="101.51200799981011" CI_START="-85.51200799981011" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="732.0" MEAN_2="724.0" MODIFIED="2011-03-17 15:59:56 +1100" MODIFIED_BY="[Empty name]" ORDER="11" SD_1="149.0" SD_2="156.5" SE="47.711084865549005" STUDY_ID="STD-Attallah-2006" TOTAL_1="20" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.04.02" MODIFIED="2013-08-01 18:19:06 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>High-flux versus low-flux dialyser</NAME>
<CONT_DATA CI_END="37.46309134923672" CI_START="-43.46309134923672" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="267.0" MEAN_2="270.0" MODIFIED="2013-08-01 18:18:30 +1000" MODIFIED_BY="Narelle S Willis" ORDER="13" SD_1="73.0" SD_2="70.0" SE="20.644813715152125" STUDY_ID="STD-Ayli-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2013-08-06 14:06:03 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="20" TOTAL_2="21" UNITS="pg" WEIGHT="0.0" Z="0.0">
<NAME>Haemoglobin content in reticulocytes (CHr)</NAME>
<GROUP_LABEL_1>Vitamin C</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vitamin C</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.3951899851447325" CI_START="0.40481001485526474" EFFECT_SIZE="0.8999999999999986" ESTIMABLE="YES" MEAN_1="30.7" MEAN_2="29.8" MODIFIED="2013-08-06 14:06:03 +1000" MODIFIED_BY="[Empty name]" ORDER="122" SD_1="0.9" SD_2="0.7" SE="0.25265259415516267" STUDY_ID="STD-Attallah-2006" TOTAL_1="20" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2013-08-06 14:03:55 +1000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="44" TOTAL_2="45" UNITS="mg/dL" WEIGHT="0.0" Z="0.0">
<NAME>C-reactive protein</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.06.01" MODIFIED="2013-08-01 18:19:33 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Vitamin C versus control</NAME>
<CONT_DATA CI_END="-0.7115045922331421" CI_START="-1.6884954077668581" EFFECT_SIZE="-1.2000000000000002" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="2.1" MODIFIED="2011-03-17 16:06:25 +1100" MODIFIED_BY="[Empty name]" ORDER="13" SD_1="0.3" SD_2="1.1" SE="0.24923693068854708" STUDY_ID="STD-Attallah-2006" TOTAL_1="20" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.06.02" MODIFIED="2013-08-01 18:19:57 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>High-flux versus low-flux dialyser</NAME>
<CONT_DATA CI_END="2.203262107979375" CI_START="-3.0032621079793755" EFFECT_SIZE="-0.40000000000000036" ESTIMABLE="YES" MEAN_1="6.3" MEAN_2="6.7" MODIFIED="2013-08-01 18:19:57 +1000" MODIFIED_BY="Narelle S Willis" ORDER="14" SD_1="4.5" SD_2="4.7" SE="1.3282193593931186" STUDY_ID="STD-Ayli-2004" TOTAL_1="24" TOTAL_2="24" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2013-08-06 14:09:51 +1000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>ESA and IV iron doses</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2013-04-18 17:30:02 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="20" TOTAL_2="21" UNITS="IU/kg/wk" WEIGHT="0.0" Z="0.0">
<NAME>EPO dose</NAME>
<GROUP_LABEL_1>Vitamin C</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Vitamin C</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.3818839558182887" CI_START="-35.61811604418171" EFFECT_SIZE="-18.0" ESTIMABLE="YES" MEAN_1="429.0" MEAN_2="447.0" MODIFIED="2011-03-17 16:13:30 +1100" MODIFIED_BY="[Empty name]" ORDER="15" SD_1="24.7" SD_2="32.5" SE="8.98899989140166" STUDY_ID="STD-Attallah-2006" TOTAL_1="20" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2013-04-18 17:27:31 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="20" TOTAL_2="21" UNITS="mg/wk" WEIGHT="0.0" Z="0.0">
<NAME>IV Iron</NAME>
<GROUP_LABEL_1>Vitamin C</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vitamin C</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="15.7475493416351" CI_START="-16.1475493416351" EFFECT_SIZE="-0.1999999999999993" ESTIMABLE="YES" MEAN_1="26.6" MEAN_2="26.8" MODIFIED="2011-03-17 16:13:30 +1100" MODIFIED_BY="[Empty name]" ORDER="16" SD_1="25.4" SD_2="26.7" SE="8.136654279072133" STUDY_ID="STD-Attallah-2006" TOTAL_1="20" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-08-07 08:46:59 +1000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-08-07 08:46:59 +1000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>The PRISMA flow chart showing selection of studies</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvIAAAIFCAYAAACwDBntAABgV0lEQVR42u2dD2SW3///vyRJMpEk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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-02-06 16:19:18 +1100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2009-10-28 15:31:08 +1100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-10-28 15:26:39 +1100" MODIFIED_BY="[Empty name]">Electronic search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2009-10-28 15:31:01 +1100" MODIFIED_BY="[Empty name]">
<TABLE COLS="2" ROWS="4">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Database</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Search terms</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>CENTRAL</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<OL>
<LI>dialysis:ti,ab,kw</LI>
<LI>(hemodia* or haemodia*):ti,ab,kw</LI>
<LI>(hemofiltration or haemofiltration):ti,ab,kw</LI>
<LI>(#1 OR #2 OR #3)</LI>
<LI>an*emia:ti,ab,kw</LI>
<LI>"iron overload":ti,ab,kw</LI>
<LI>(#5 OR #6)</LI>
<LI>erythropo*etin:ti,ab,kw</LI>
<LI>(erythropo*esis next stimulating next agent*):ti,ab,kw</LI>
<LI>(continuous next erythropo*esis next receptor next activator*):ti,ab,kw</LI>
<LI>EPO:ti,ab,kw</LI>
<LI>rhEPO:ti,ab,kw</LI>
<LI>epo*etin:ti,ab,kw</LI>
<LI>Eprex:ti,ab,kw</LI>
<LI>Epogen:ti,ab,kw</LI>
<LI>Procrit:ti,ab,kw</LI>
<LI>darbepo*etin:ti,ab,kw</LI>
<LI>aranesp:ti,ab,kw</LI>
<LI>neorecormon:ti,ab,kw</LI>
<LI>CERA:ti,ab,kw</LI>
<LI>mircera:ti,ab,kw</LI>
<LI>(#8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21)</LI>
<LI>(#4 AND #7 AND #22)</LI>
</OL>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MEDLINE</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<OL>
<LI>exp Renal Dialysis/</LI>
<LI>dialysis.tw.</LI>
<LI>(hemodialysis or haemodialysis).tw.</LI>
<LI>(hemofiltration or haemofiltration).tw.</LI>
<LI>(hemodiafiltration or haemodiafiltration).tw.</LI>
<LI>or/1-5</LI>
<LI>Anemia/</LI>
<LI>Anemia,Refractory/</LI>
<LI>Iron Overload/</LI>
<LI>(an?emia or an?emic).tw.</LI>
<LI>or/7-10</LI>
<LI>exp Erythropoietin/</LI>
<LI>erythropoiesis stimulating agent$.tw.</LI>
<LI>erythropo?etin.tw.</LI>
<LI>EPO.tw.</LI>
<LI>rhEPO.tw.</LI>
<LI>epo?etin.tw.</LI>
<LI>Eprex.tw.</LI>
<LI>Epogen.tw.</LI>
<LI>Procrit.tw.</LI>
<LI>darbepo?etin.tw.</LI>
<LI>aranesp.tw.</LI>
<LI>neorecormon.tw.</LI>
<LI>continuous erythropo?esis receptor activator.tw.</LI>
<LI>CERA.tw.</LI>
<LI>Mircera.tw.</LI>
<LI>or/12-26</LI>
<LI>and/6, 11, 27</LI>
</OL>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EMBASE</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<OL>
<LI>Anemia/</LI>
<LI>Refractory Anemia/</LI>
<LI>Iron Overload/</LI>
<LI>(an?emia or an?emic).tw.</LI>
<LI>or/1-4</LI>
<LI>Erythropoietin/</LI>
<LI>Recombinant Erythropoietin/</LI>
<LI>erythropo?esis stimulating agent$.tw.</LI>
<LI>erythropo?etin.tw.</LI>
<LI>EPO.tw.</LI>
<LI>rhEPO.tw.</LI>
<LI>epo?etin.tw.</LI>
<LI>Eprex.tw.</LI>
<LI>Epogen.tw.</LI>
<LI>Procrit.tw.</LI>
<LI>darbepo?etin.tw.</LI>
<LI>aranesp.tw.</LI>
<LI>neorecormon.tw.</LI>
<LI>continuous erythropo?esis receptor activator.tw.</LI>
<LI>CERA.tw.</LI>
<LI>Mircera.tw.</LI>
<LI>or/6-21</LI>
<LI>exp Renal Replacement Therapy/</LI>
<LI>dialysis.tw.</LI>
<LI>(hemodialysis or haemodialysis).tw.</LI>
<LI>(hemofiltration or haemofiltration).tw.</LI>
<LI>(hemodiafiltration or haemodiafiltration).tw.</LI>
<LI>or/23-27</LI>
<LI>and/5, 22, 28</LI>
</OL>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-02-06 16:19:18 +1100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-05-18 13:46:50 +1000" MODIFIED_BY="Narelle S Willis">Risk of bias assessment tool</TITLE>
<APPENDIX_BODY MODIFIED="2013-02-06 16:19:18 +1100" MODIFIED_BY="Narelle S Willis">
<TABLE COLS="2" ROWS="22">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Potential source of bias</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Assessment criteria</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Random sequence generation</B>
</P>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>Random number table; computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots; minimization (minimization may be implemented without a random element, and this is considered to be equivalent to being random).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Sequence generated by odd or even date of birth; date (or day) of admission; sequence generated by hospital or clinic record number; allocation by judgement of the clinician; by preference of the participant; based on the results of a laboratory test or a series of tests; by availability of the intervention.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information about the sequence generation process to permit judgement.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Allocation concealment</B>
</P>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>Randomisation method described that would not allow investigator/participant to know or influence intervention group before eligible participant entered in the study (e.g. central allocation, including telephone, web-based, and pharmacy-controlled, randomisation; sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non-opaque or not sequentially numbered); alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear</I>: Randomisation stated but no information on method used is available.</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>
<B>Blinding of participants and personnel</B>
</P>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</TD>
<TD>
<P>
<I>Low risk of bias</I>:<I> </I>No blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding; blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias</I>: No blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding; blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear</I>: Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Blinding of outcome assessment</B>
</P>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors.</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>No blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding; blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>No blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding; blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Incomplete outcome data</B>
</P>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data.</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>No missing outcome data; reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size; missing data have been imputed using appropriate methods.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size; &#8216;as-treated&#8217; analysis done with substantial departure of the intervention received from that assigned at randomisation; potentially inappropriate application of simple imputation.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Selective reporting</B>
</P>
<P>Reporting bias due to selective outcome reporting</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>The study protocol is available and all of the study&#8217;s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way; the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified (convincing text of this nature may be uncommon).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Not all of the study&#8217;s pre-specified primary outcomes have been reported; one or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre-specified; one or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); one or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis; the study report fails to include results for a key outcome that would be expected to have been reported for such a study.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Other bias</B>
</P>
<P>Bias due to problems not covered elsewhere in the table</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>The study appears to be free of other sources of bias.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias:</I> Had a potential source of bias related to the specific study design used; stopped early due to some data-dependent process (including a formal-stopping rule); had extreme baseline imbalance; has been claimed to have been fraudulent; had some other problem.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to assess whether an important risk of bias exists; insufficient rationale or evidence that an identified problem will introduce bias.</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;Studies included: 2 (4 reports)&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;Full text reports assessed: 99&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;Records screened: 521&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;Reports identified: 533&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;Records identified through database searching: 517&lt;br&gt;(MEDLINE; EMBASE; CENTRAL; Renal Group's specialised register)&lt;/p&gt;" WIDTH="300"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;Records identified from other sources: 16&lt;/p&gt;" WIDTH="300"/>
<OUT TEXT="&lt;p&gt;Duplicates removed: 12&lt;/p&gt;" WIDTH="250"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;Records excluded: 428&lt;br&gt;(title and abstract review)&lt;/p&gt;" WIDTH="250"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;Excluded studies: 68 (93 reports)&lt;/p&gt;&lt;p&gt;Study participants did not have ESA resistance (57); not RCT (6); wrong population (3); ESA not used in control arm (1); ESA not used (1)&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="250"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;Ongoing studies: 2&lt;/p&gt;"/>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>